(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 May 2005 (06.05.2005)

PCT

(10) International Publication Number
WO 2005/040151 A1

(51) International Patent Classification[7]: C07D 401/04, 401/14, 409/14, 405/14, A61K 31/4965

(21) International Application Number:
PCT/JP2004/016193

(22) International Filing Date: 25 October 2004 (25.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2003905895 27 October 2003 (27.10.2003) AU
2004902764 24 May 2004 (24.05.2004) AU

(71) Applicant (*for all designated States except US*): FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).

(72) Inventors; and
(75) Inventors/Applicants (*for US only*): YONISHI, Satoshi [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). AOKI, Satoshi [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). MATSUSHIMA, Yuji [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). AKAHANE, Atsushi [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).

(74) Agent: TABUSHI, Eiji; c/o Fujisawa Pharmaceutical Co., Ltd., Osaki Factory, 1-6, Kashima 2-chome,, Yodogawa-ku, Osaki-shi, OSAKA 532-8514 (JP).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/040151 A1

(54) Title: PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF



(I)

(57) Abstract: A pyrazine derivative of the following formula (I): or a salt thereof. The pyrazine compound (I) and a salt thereof of the present invention are adenosine antagonists and are useful for the prevention and/or treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's, disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke), etc.), heart failure and the like.

DESCRIPTION

PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF

TECHNICAL FIELD

The present invention relates to a novel pyrazine derivative and a salt thereof, which are useful as medicaments.

BACKGROUND ART

Adenosine is a ubiquitous biochemical messenger. Adenosine binds to and activates seven-transmembrane spanning G-protein coupled receptors, eliciting a variety of physiological responses. Adenosine receptors are divided into four known subtypes (i.e., A_1, A_{2a}, A_{2b}, and A_3). These receptor subtypes mediate different, and sometimes opposing, effects. Activation of the adenosine A_1 receptor, for example, elicits an increase in renal vascular resistance, while activation of the adenosine A_{2a} receptor elicits a decrease in renal vascular resistance. Accordingly, adenosine antagonists are useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.

Some 2-aminopyridine compounds to exhibit adenosine receptor antagonism are known (WO 02/14282, WO 01/25210,

etc.), and some 2-aminopyrimidine compounds are also known (US 2001/0027196, etc.).

However, it is generally difficult to produce a pyrazine which is substituted by four different substituents, and for example the synthesis of a pyrazine compound of the formula A :



(A)

wherein Ar and Ar' are independently same or different aryl; and

R, R' and M are independently hydrogen or suitable substituent;

is reported (e.g. (1) *J. Org. Chem.*, **40**, 2341 (1975)., (2) *J. Heterocyclic Chem.*, **15**, 665 (1978), (3) *J. Chem. Soc., Perkin Trans. 1*, 885 (1994)., (4) *Synthesis*, 931 (1994)., (5) WO-02/088084, etc.), however the Ar and Ar' thereof are same, and the selective synthesis of a pyrazine compound A wherein Ar and Ar' are different is not shown as far as we know, and 2-amino-6-aryl-5-(6-oxo-1,6-dihydro-pyrid-3-yl)-pyrazine compounds and derivatives thereof are novel, so there has been no knowledge about these compounds, so far. In addition, any pyrazine derivatives having both of adenosine A_1 and A_{2a} inhibitory activities are not known.

DISCLOSURE OF INVENTION

The present invention relates to a novel pyrazine derivative and a pharmaceutically acceptable salt thereof, which are useful as medicaments with no or less toxicity (particularly the convulsive toxicity); processes for preparing the preparation of pyrazine derivative and a salt thereof; a pharmaceutical composition comprising, as an active ingredient, said pyrazine derivative or a pharmaceutically acceptable salt thereof; a use of said pyrazine derivative or a pharmaceutically acceptable salt thereof as a medicament; and a method for using said pyrazine derivative or a pharmaceutically acceptable salt thereof for therapeutic purposes, which comprises administering said pyrazine derivative or a pharmaceutically acceptable salt thereof to a human being or an animal.

The pyrazine derivatives and a salt thereof are adenosine antagonists (especially, A_1 receptor and A_2 (particularly A_{2a}) receptor dual antagonists) and possess various pharmacological actions such as anticatalepsy action, cognitive enhancing action, analgesic action, locomotor action, antidepressant action, diuretic action, cardioprotective action, cardiotonic action, vasodilating action (e.g. cerebral vasodilating action, etc.), the action of increasing the renal blood flow, renal protective

action, improvement action of renal function, enhancing action of lipolysis, inhibition action of anaphylactic bronchoconstriction, acceleration action of the insulin release, the action of increasing the production of erythropoietin, inhibiting action of platelet aggregation, or the like.

They are useful as cognitive enhancer, antianxiety drug, antidementia drug, psychostimulant, analgesic, cardioprotective agent, antidepressant, ameliorants of cerebral circulation, tranquilizer, drug for heart failure, cardiotonic agent, antihypertensive agent, drug for renal failure (renal insufficiency), drug for renal toxicity, renal protective agent, drug for improvement of renal function, diuretic, drug for edema, antiobesity, antiasthmatic, bronchodilator, drug for apnea, drug for gout, drug for hyperuricemia, drug for sudden infant death syndrome (SIDS), ameliorants of immunosuppressive action of adenosine, antidiabetic agent, drug for ulcer, drug for pancreatitis, drug for Meniere's syndrome, drug for anemia; drug for thrombosis, drug for myocardial infarction, drug for obstruction, drug for arteriosclerosis obliterans, drug for thrombophlebitis, drug for cerebral infarction, drug for transient ischemic attack, drug for angina pectoris, or the like; and useful for the prevention and/or treatment of depression, dementia (e.g. Alzheimer's

disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure; hypertension (e.g. essential hypertension, nephrogenous hypertension, etc.); circulatory insufficiency (acute circulatory insufficiency) caused by, for example, ischemia/reperfusion injury (e.g. myocardial ischemia/reperfusion injury, cerebral ischemia/reperfusion injury, peripheral ischemia/reperfusion injury, etc.), shock (e.g. endotoxin shock, hemorrhagic shock, etc.), surgical procedure, or the like; post-resuscitation asystole; bradyarrhythmia; electro-mechanical dissociation; hemodynamic collapse; SIRS (systemic inflammatory response syndrome); multiple organ failure; renal failure (renal insufficiency) (e.g. acute renal failure, etc.), renal toxicity [e.g. renal toxicity induced by a drug such as cisplatins, gentamicin, FR-900506 (disclosed in EP-0184162), cyclosporin (e.g. cyclosporin A) or the like; glycerol, etc.], nephrosis, nephritis, edema (e.g. cardiac edema, nephrotic edema, hepatic edema, idiopathic edema, drug edema, acute angioneurotic edema, hereditary angioneurotic edema, carcinomatous ascites, gestational edema, etc.); obesity, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, ulcer such as

peptic ulcer (e.g. gastric ulcer, duodenal ulcer, etc.), pancreatitis, Meniere's syndrome, anemia, dialysis-induced hypotension, constipation, ischemic bowel disease, ileus (e.g. mechanical ileus, adynamic ileus, etc.); and myocardial infarction, thrombosis (e.g. arterial thrombosis, cerebral thrombosis, etc.), obstruction, arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient ischemic attack, angina pectoris, or the like.

The novel pyrazine derivative or a salt thereof of the present invention can be shown by the following formula (I):



(I)

wherein

R^1 is  or 

wherein

R^6 is hydrogen, or optionally substituted lower alkyl;

R^7 is hydrogen or halogen;

R^8 is lower alkyl;

R^2 is hydrogen; hydroxy; halogen; cyano; or lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, aryloxy, arylthio, acyl, aryl, heterocyclic group or amino, each of which is optionally substituted by substituent(s);

R^3 and R^4 are independently hydrogen, lower alkyl or acyl; and

R^5 is lower alkyl, lower alkenyl, lower alkynyl, cyano, aryl or heterocyclic group, each of which is optionally substituted by substituent(s);

or a salt thereof.

The preferred embodiments of the pyrazine compound of the present invention represented by the general formula (I) are as follows.

(1) The pyrazine compound of the general formula (I) wherein

R^1 is  ;

wherein

R^6 is hydrogen, lower alkyl, aryl(lower)alkyl, heteroaryl(lower)alkyl;

R^7 is hydrogen or halogen;

R^2 is hydrogen, halogen, cyano, optionally substituted

lower alkyl, optionally substituted lower alkynyl, lower alkoxy, aryloxy, arylthio, carbamoyl, carboxy, protected carboxy or optionally substituted amino;

R^3 and R^4 are independently hydrogen or lower alkyl; and

R^5 is aryl or heteroaryl each of which is optionally substituted by one or more substituent(s);

or a salt thereof.

(2) The pyrazine compound of (1) above wherein

R^2 is hydrogen, halogen, cyano, hydroxylated(lower)alkyl, lower alkynyl, lower alkoxy, aryloxy, arylthio, carboxy, esterified carboxy, carbamoyl, amidated carboxy, amino or mono- or di-(lower)alkylamino;

R^3 and R^4 are independently hydrogen;

R^5 is aryl or heteroaryl, each of which is optionally substituted by one or more substituent(s) selected from the group consisting of halogen and lower alkoxy;

R^6 is hydrogen or lower alkyl; and

R^7 is hydrogen;

or a salt thereof.

(3) The pyrazine compound of (2) above

wherein

R^2 is hydrogen, bromo, cyano, hydroxymethyl, hydroxyethyl, hydroxypropyl, ethynyl, methoxy, ethoxy, propoxy, phenyloxy, phenylthio, carboxy, carbamoyl, mono- or di-methylaminocarbonyl, pyridylmethylaminocarbonyl, hydroxymethylaminocarbonyl or mono- or di-methylamino;

R^3 and R^4 are independently hydrogen;

R^5 is phenyl, pyridyl, furyl, thienyl, pyrrolyl or pyrazolyl, each of which is optionally substituted by one or more substituent(s) selected from the group consisting of fluoro, chloro and methoxy;

R^6 is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl or *t*-butyl ; and

R^7 is hydrogen;

or a salt thereof.

(4) The pyrazine compound of (3) above

wherein

R^2 is hydrogen, cyano, ethynyl, methoxy, phenyloxy, phenylthio, carboxy, carbamoyl or methylamino; and

R^5 is phenyl, furyl or thienyl, each of which is optionally substituted by one or more substituent(s) selected from the group consisting

of fluoro, chloro and methoxy;

or a salt thereof.

(5) The pyrazine compound of (4) above wherein

R^2 is hydrogen, cyano, carboxy, carbamoyl or methylamino;

R^5 is phenyl which is optionally substituted by one or more fluoro; and

R^6 is hydrogen, methyl, ethyl or isopropyl;

or a salt thereof.

The object compound (I) and a salt thereof of the present invention can be prepared by the following processes.

Process 1



(II) or a salt thereof (III) or a salt thereof (I) or a salt thereof

Process 2



(Ia) or a salt thereof (Iba) or a salt thereof

Process 3



(Ib) (IV) (Ic)

or a salt thereof or a salt thereof or a salt thereof

Process 4



(Id) (Ie)

or a salt thereof or a salt thereof

Process 5



(Ie) (If)

or a salt thereof or a salt thereof

Process 6



(Ie) (Ig)

or a salt thereof or a salt thereof

Process 7

(If)
or a salt thereof

(Ih)
or a salt thereof

Process 8



(Ih)
or a salt thereof

(V)
or a salt thereof

(Ij)
or a salt thereof

[wherein R^1, R^2, R^3, R^4, R^5 and R^8 are each as defined above;

R^9 is cyano, carbamoyl or carboxy;

R^{10} is optionally substituted lower alkyl;

R^{11} and R^{12} are independently hydrogen, lower alkyl, lower alkoxy or cyclo(lower)alkyl, each of which is optionally substituted by substituent(s); or R^{11} and R^{12}, together with the nitrogen atom to which they are attached, represent a optionally substituted N-containing heterocyclic group;

R^{13} is lower alkyl, lower alkenyl, lower alkynyl,

lower alkoxy, aryloxy, arylthio, acyl, aryl, heterocyclic group or amino, each of which is optionally substituted by substituent(s);

Y is a leaving group;

Hal is a halogen atom; and

Z is hydrogen, an alkali metal (e.g. lithium, sodium, potassium, etc.), $SnBu_3$, BW_2 or Met-Hal;

wherein BW_2 is a part of organoboron compound such as $B(OH)_2$, $B(CHCH_3CH(CH_3)_2)_2$, tetramethyl-1,3,2-dioxaborolan-2-yl, 9-borabicyclo[3.3.1]nonanyl, or the like; and

Met-Hal is a part of metalhalide compound such as MgBr, ZnCl, or the like.]

The starting compounds or a salt thereof can be prepared, for example, by the following reaction schemes.

Process A



(VI) or a salt thereof

(VII) or a salt thereof

(VIII) or a salt tehreof

(IV) or a salt thereof

Process B



(IX) or a salt thereof (X) or a salt thereof (XI) or a salt thereof

Process C



(XI) or a salt thereof (XII) or a salt thereof

Process D



(XIII) or a salt thereof (XIV) or a salt thereof

Process E



(XV) or a salt thereof (XVI) or a salt thereof (II) or a salt thereof

[wherein R^1, R^2, R^3, R^4, R^{10}, Y and Hal are each as defined

above.]

In addition to the processes as mentioned above, the object compound (I) and a salt thereof can be prepared, for example, according to the procedures as illustrated in Examples in the present specification or in a manner similar thereto.

The starting compounds can be prepared, for example, according to the procedures as illustrated in Preparations in the present specification or in a manner similar thereto.

The object compound (I) and a salt thereof can be prepared according to the methods as shown in Preparations or Examples, or in a manner similar thereto.

It is also to be noted that the solvating form of the compound (I) (e.g. hydrate, etc.) and any form of the crystal of the compound (I) are included within the scope of the present invention.

It is also to be noted that radiolabelled derivatives of the compound (I), which are suitable for biological studies, are included within the scope of the present invention.

Suitable salts of the object compound (I) are conventional pharmaceutically acceptable ones and include a metal salt such as an alkali metal salt (e.g. sodium salt, potassium salt, etc.) and an alkaline earth metal salt (e.g.

calcium salt, magnesium salt, etc.), an ammonium salt, an organic base salt (e.g. trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.), an organic acid salt (e.g. acetate, trifluoroacetate, maleate, tartrate, fumarate, methanesulfonate, benzenesulfonate, formate, toluenesulfonate, etc.), an inorganic acid salt (e.g. hydrochloride, hydrobromide, hydriodide, sulfate, phosphate, etc.), a salt with an amino acid (e.g. arginine, aspartic acid, glutamic acid, etc.), and the like.

Suitable examples and illustrations of the various definitions which the present invention includes within the scope thereof and which appear in the above and following description in the present specification are explained in detail as follows.

The term "optionally substituted" refers to "unsubstituted or substituted".

The term "lower" is intended to mean 1 to 6 carbon atom(s) unless otherwise indicated.

Suitable "lower alkyl" and "(lower)alkyl" moiety in the term of "mono- or di-(lower)alkylamino" may include straight or branched ones such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl or the like, in which the preferred one may be methyl, ethyl or isopropyl.

Suitable "optionally substituted lower alkyl" may include lower alkyl which is optionally substituted by suitable substituent(s) such as lower alkoxy, hydroxy, aryloxy, cyclo(lower)alkyl, amino, aryl, heterocyclic group, acyl or the like.

Suitable "lower alkoxy" may include straight or branched ones such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy or the like.

Suitable "optionally substituted lower alkoxy" may include lower alkoxy which is optionally substituted by suitable substituent(s) such as hydroxy, cyclo(lower)alkyl, amino, aryl, heterocyclic group, acyl or the like.

Suitable "cyclo(lower)alkyl" may be cyclo(C3-C8)alkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or the like, in which the preferred one may be cyclohexyl.

Suitable "lower alkenyl" may include straight or branched ones such as vinyl, propenyl, allyl, isopropenyl, butenyl, pentenyl, hexenyl or the like, in which the preferred one may be vinyl.

Suitable "optionally substituted lower alkenyl" may include lower alkenyl which is optionally substituted by suitable substituent(s) such as lower alkoxy, hydroxy, cyclo(lower)alkyl, amino, aryl, heterocyclic group, acyl or the like.

Suitable "lower alkynyl" may include straight or branched ones such as ethynyl, propynyl, butynyl, pentynyl, hexynyl or the like, in which the preferred one may be ethynyl.

Suitable "optionally substituted lower alkynyl" may include lower alkynyl which is optionally substituted by suitable substituent(s) such as lower alkoxy, hydroxy, cyclo(lower)alkyl, amino, aryl, heterocyclic group, acyl or the like.

Suitable "aryl" and "aryl" moiety in the term of "aryloxy" or "arylthio" may include phenyl, naphthyl, indenyl, anthryl, or the like, in which the preferred one may be (C6-C10) aryl, and the more preferred one may be phenyl.

Suitable "aryl(lower)alkyl" may include phenyl(lower)alkyl (e.g. benzyl, phenethyl, etc.), diphenyl(lower)alkyl (e.g. benzhydryl, etc.), triphenyl(lower)alkyl (e.g. trityl, etc.), naphthyl(lower)alkyl, indenyl(lower)alkyl or anthryl(lower)alkyl and the like, in which the preferred one may be phenyl(lower)alkyl, and the more preferred one may be phenyl(C1-C4)alkyl.

Suitable "optionally substituted aryl" may include aryl which is optionally substituted by suitable substituent(s), preferably 1 to 3 substituent(s), such as

lower alkyl, lower alkoxy, hydroxy, halogen, etc. Suitable examples of optionally substituted aryl include lower alkylphenyl, lower alkoxyphenyl and halophenyl.

Suitable "heterocyclic group" may be saturated or unsaturated monocyclic or polycyclic heterocyclic groups containing at least one heteroatom selected from among oxygen, sulfur and nitrogen.

The particularly preferred example of said heterocyclic group may include

3- through 8-membered unsaturated heteromonocyclic groups containing 1 through 4 nitrogen atom(s), such as pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl and its N-oxide, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl (e.g. 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.), tetrazolyl (e.g. 1H-tetrazolyl, 2H-tetrazolyl, etc.), dihydrotriazinyl (e.g. 4,5-dihydro-1,2,4-triazinyl, 2,5-dihydro-1,2,4-triazinyl, etc.), etc.;

3- through 8-membered saturated heteromonocyclic groups containing 1 through 4 nitrogen atom(s), such as azetidinyl, pyrrolidinyl, imidazolidinyl, piperidyl (e.g. piperidino, etc.), piperazinyl, etc.;

unsaturated condensed heterocyclic groups containing 1 through 5 nitrogen atom(s), such as indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl,

isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridyl, tetrazolopyridazinyl (e.g. tetrazolo[1,5-b]pyridazinyl etc.), dihydrotriazolopyridazinyl, etc.;

3- through 8-membered unsaturated heteromonocyclic groups containing 1 or 2 oxygen atoms and 1 through 3 nitrogen atom(s), such as oxazolyl, isoxazolyl, oxadiazolyl (e.g. 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl, etc.), etc.;

3- through 8-membered saturated heteromonocyclic groups containing 1 or 2 oxygen atom(s) and 1 through 3 nitrogen atoms, such as morpholinyl, oxazolidinyl (e.g. 1,3-oxazolidinyl etc.), etc.;

unsaturated condensed heterocyclic groups containing 1 or 2 oxygen atom(s) and 1 through 3 nitrogen atom(s), such as benzoxazolyl, benzoxadiazolyl, etc.;

3- through 8-membered unsaturated heteromonocyclic groups containing 1 or 2 sulfur atom(s) and 1 through 3 nitrogen atom(s), such as thiazolyl, isothiazolyl, thiazolinyl, thiadiazolyl (e.g. 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,2,3-thiadiazolyl), etc.;

3- through 8-membered saturated heteromonocyclic groups containing 1 or 2 sulfur atom(s) and 1 through 3 nitrogen atom(s), such as thiazolidinyl etc.;

3- through 8-membered unsaturated heteromonocyclic

groups containing 1 sulfur atom, such as thienyl etc.;

unsaturated condensed heterocyclic groups containing 1 or 2 sulfur atoms and 1 through 3 nitrogen atom(s), such as benzothiazolyl, benzothiadiazolyl, etc.;

3- through 8-membered unsaturated heteromonocyclic groups containing 1 or 2 oxygen atom(s), such as furyl, pyranyl, dioxolyl, etc.;

3- through 8-membered saturated heteromonocyclic groups containing 1 or 2 oxygen atom(s), such as oxolanyl, tetrahydropyranyl (e.g. tetrahydro-2H-pyran-2-yl etc.), dioxolanyl, etc.; and

unsaturated condensed heterocyclic groups containing 1 or 2 oxygen atom(s), such as isobenzofuranyl, chromenyl (e.g. 2H-chromen-3-yl etc.), dihydrochromenyl (e.g. 3,4-dihydro-2H-chromen-4-yl etc.), etc.

Suitable "optionally substituted heterocyclic group" may include heterocyclic group which is optionally substituted by suitable substituent(s), preferably 1 to 3 substituent(s), such as lower alkyl, lower alkoxy, hydroxy, halogen, or the like.

Suitable "N-containing heterocyclic group" may be aforesaid "heterocyclic group", in which said group contains at least one N atom in its ring members, such as pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, dihydrotriazinyl, azetidinyl, pyrrolidinyl,

imidazolidinyl, piperidyl, piperazinyl, indolyl, isoindolyl, indazolyl, benzotriazolyl, dihydrotriazolopyridazinyl, morpholinyl, oxazolidinyl, thiazolynyl, thiazolidinyl, etc.

Suitable "heteroaryl" and "heteroaryl" moiety in the term of "heteroaryl(lower)alkyl" may be aforesaid "heterocyclic group", in which those categorized as an aromatic heterocyclic group, such as pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, tetrazolyl, dihydrotriazinyl, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridyl, tetrazolopyridazinyl, dihydrotriazolopyridazinyl, oxazolyl, isoxazolyl, oxadiazolyl, benzoxazolyl, benzoxadiazolyl, thiazolyl, isothiazolyl, thiazolinyl, thiadiazolyl, thienyl, benzothiazolyl, benzothiadiazolyl, furyl, pyranyl, dioxolyl, isobenzofuranyl, chromenyl, dihydrochromenyl, etc.

Suitable "acyl" may include lower alkanoyl, aroyl, carboxy, protected carboxy, and the like.

Suitable examples of aforesaid "lower alkanoyl" may be formyl, acetyl, propionyl, butyryl, isobutyryl, pivaloyl, hexanoyl, or the like, in which the preferred one may be (C1-C4)alkanoyl.

Suitable examples of aforesaid "aroyl" may be benzoyl, toluoyl, or the like.

Suitable examples of aforesaid "protected carboxy" may be

i) esterified carboxy, in which suitable esterified carboxy may include lower alkoxycarbonyl (e.g. methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, t-butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl, etc.), aryl(lower)alkoxycarbonyl (e.g. benzyloxycarbonyl, phenethyloxycarbonyl, 2-phenylpropoxycarbonyl, 4-phenylbutoxycarbonyl, 4-phenylpentyloxycarbonyl, 1,3-diphenylhexyloxycarbonyl, etc.), and the like;

ii) amidated carboxy, in which suitable amidated carboxy may include carbamoyl, N-(lower)alkylcarbamoyl (e.g. N-methylcarbamoyl, N-ethylcarbamoyl, N-isopropylcarbamoyl, N-butylcarbamoyl, N-pentylcarbamoyl, N-hexylcarbamoyl, etc.), N,N-di(lower)alkylcarbamoyl [e.g. N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, N,N-dipropylcarbamoyl, N,N-di(t-butyl)carbamoyl, N-pentyl-N-hexylcarbamoyl, etc.], N-lower alkyl-N-aryl(lower)alkylcarbamoyl (e.g. N-methyl-N-benzylcarbamoyl, etc), and the like.

Suitable "halogen" may be fluoro, chloro, bromo and

iodo.

Suitable "a leaving group" may include halogen, hydroxy, acyloxy such as alkanoyloxy (e.g. acetoxy, propionyloxy, etc.) or sulfonyloxy (e.g. mesyloxy, tosyloxy, etc.), or the like.

Suitable "optionally substituted amino" may include amino, mono- or di-(lower)alkylamino (e.g. methylamino, dimethylamino, methylethylamino, etc.), acylamino (e.g. lower alkoxycarbonylamino (e.g. methoxycarbonylamino, ethoxycarbonylamino, etc.), sulfonylamino (e.g. mesylamino, etc.), ureido, etc.), or the like.

The processes for preparing the object pyrazine compound (I) are explained in detail in the following.

Process 1

The compound (I) or a salt thereof can be prepared by subjecting the compound (II) or a salt thereof to coupling reaction with the compound (III) or a salt thereof.

This reaction is usually carried out in a conventional solvent such as water, acetone, dioxane, acetonitrile, 1,2-dimethoxyethane, chloroform, dichloromethane, 1,2-dichloroethane, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, methanol, ethanol, diethyl ether, 1,3-dimethyl-2-imidazolidinone,

N-methylpyrrolidone, N,N'-dimethylpropyleneurea, a mixture thereof or any other organic solvent which does not adversely affect the reaction.

Some of the present reaction is preferably carried out in the presence of an organic or inorganic base such as an alkali metal (e.g. sodium, potassium, etc.), an alkaline earth metal (e.g. magnesium, calcium, etc.), the hydride or hydroxide or alkoxide or carbonate or hydrogencarbonate or alkanoic acid thereof, trialkylamine (e.g. triethylamine, trimethylamine, etc.), hydrazine, pyridine compound (e.g. pyridine, lutidine, picoline, 4-dimethylaminopyridine, etc.), quinoline, and the like.

Some of the present reaction is preferably carried out in the presence of a catalyst such as palladium(II) acetate, tetrakis(triphenylphosphine) palladium(0), and the like.

The reaction temperature is not critical, and the reaction is usually carried out at ambient temperature, under warming or heating.

Process 2

The compound (Iba) or a salt thereof can be prepared by subjecting the compound (Ia) or a salt thereof to hydrolysis.

This reaction is carried out in accordance with a conventional method.

The hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.

Suitable base includes an inorganic base and an organic base such as an alkali metal (e.g. sodium, potassium, etc.), an alkaline earth metal (e.g. magnesium, calcium, etc.), the hydroxide or carbonate or hydrogencarbonate thereof, trialkylamine (e.g. triethylamine, trimethylamine, etc.), hydrazine, pyridine compound (e.g. pyridine, lutidine, picoline, 4-dimethylaminopyridine, etc.), 1,5-diazabicyclo[4.3.0]non-5-ene, quinoline, 1,4-diazabicyclo[2.2.2]octane, 1,8-diazabicyclo[5.4.0]undec-7-ene, or the like.

Suitable acid includes an organic acid (e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.) and an inorganic acid (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.).

The elimination using Lewis acid such as boron tribromide, boron trichloride, boron trifluoride, aluminum chloride or the like is preferably carried out in the presence of cation trapping agents (e.g. anisole, phenol, etc.).

The hydrolysis in this case usually carried out in the presence of an acid including Lewis acid, and these acid(s) including Lewis acid(s) can be used in the mixture,

and the point(s) or the number of being hydrolyzed can be different by the condition (see the example part (examples 2, 7, 10 and 15) in detail).

The reaction is usually carried out in a solvent such as water, an alcohol (e.g. methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, dichloromethane, 1,2-dichloroethane, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide, or any other organic solvent which does not adversely affect the reaction, or a mixture thereof.

A liquid base or acid can be also used as the solvent.

The reaction temperature is not critical and the reaction is usually carried out under cooling to heating.

Process 3

The compound (Ic) or a salt thereof can be prepared by subjecting the compound (Ib) or a salt thereof to the alkylation with the compound (IV) or a salt thereof.

Suitable salt of the compound (IV) can be referred ones as exemplified for the compound (I).

This reaction is carried out in a solvent such as water, phosphate buffer, acetone, chloroform, acetonitrile, nitrobenzene, dichloromethane, 1,2-dichloroethane, formamide, N,N-dimethylformamide, methanol, ethanol, sec-butanol, amyl alcohol, diethyl ether, dioxane, 1,2-dimethoxyethane, tetrahydrofuran, dimethyl sulfoxide,

or any other organic solvent which does not adversely affect the reaction, preferably in ones having strong polarities. Among the solvents, hydrophilic solvents may be used in a mixture with water. When the compound (IV) is in a liquid state, it can also be used as a solvent. The reaction is preferably conducted in the presence of a base, for example, inorganic base such as alkali metal hydroxide, alkali metal alkoxide (e.g. potassium *t*-butoxide), alkali metal carbonate, alkali metal bicarbonate, alkali metal hydride (e.g. sodium hydride, etc.), or organic base such as trialkylamine (e.g. triethylamine, etc.), or basic resin, and the like.

The reaction temperature is not critical, and the reaction is usually carried out at ambient temperature, under warming or heating.

The present reaction is preferably carried out in the presence of alkali metal halide (e.g. sodium iodide, potassium iodide, etc.), or the like.

When Y is -OH, activation of OH with triphenylphosphine, or the like, and di (lower) alkyl azodicarboxylate (e.g. diethyl azodicarboxylate, diisopropyl azodicarboxylate, etc.), or the like, may be necessary.

Process 4

The compound (Ie) or a salt thereof can be prepared

by subjecting the compound (Id) or a salt thereof to hydrolysis using a base or an acid.

This reaction can be carried out in the same manner as the aforementioned hydrolysis using a base in Process 2, and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process 2.

Process 5

The compound (If) or a salt thereof can be prepared by decarboxylation of the compound (Ie) or a salt thereof.

This reaction is carried out in accordance with a conventional method such as thermal decomposition, acid decomposition and the like; more suitable one in this case is thermal decomposition.

The reaction is usually carried out in a conventional inactive solvent such as quinoline, dichlorobenzene, mesitylene, dodecane, Dowtherm® (phenyl ether-biphenyl eutectic mixture) or any other organic solvent which does not adversely affect the reaction, or a mixture thereof; more suitable one in this case is 1,2-dichlorobenzene.

The reaction temperature is not critical, and the reaction is usually carried out on 100°C-200°C heating condition.

Process 6

The compound (Ig) or a salt thereof can be prepared

by amidation of the compound (Ie) or a salt thereof.

The reaction is usually carried out in a conventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, dichloromethane, 1,2-dichloroethane, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvent which does not adversely affect the reaction, or a mixture thereof.

The reaction is preferably carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethyl-carbodiimide; N-cyclohexyl-N'-(4-diethylaminocyclohexyl)-carbodiimide; N,N'-diisopropylcarbodiimide; N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide; N,N-carbonyl-bis-(2-methylimidazole); pentamethyleneketene-N-cyclohexylimine; diphenylketene-N-cyclohexylimine; ethoxyacetylene; 1-alkoxy-1-chloroethylene; trialkyl phosphite; isopropyl polyphosphate; phosphorus oxychloride (phosphoryl chloride); phosphorus trichloride; thionyl chloride; oxalyl chloride; triphenylphosphine; 2-ethyl-7-hydroxybenzisoxazolium salt; 2-ethyl-5-(*m*-sulfophenyl)isoxazolium hydroxide intramolecular salt; 1-(p-chlorobenzenesulfonyloxy)-6-chloro-1H-benzotriazole; so-called Vilsmeier reagent prepared by the reaction of N,N-dimethylformamide with

thionyl chloride, phosgene, phosphorus oxychloride, etc.; or the like.

The reaction may also be carried out in the presence of an organic or inorganic base such as an alkali metal bicarbonate, tri(lower)alkylamine, pyridine, N-(lower)-alkylmorpholine, N,N-di(lower)alkylbenzylamine, or the like.

The reaction temperature is not critical, and the reaction is usually carried out under cooling to heating.

Process 7

The compound (Ih) or a salt thereof can be prepared by subjecting the compound (If) or a salt thereof to halogenation with a halogenating agent such as N-halosuccinimide (e.g. N-chlorosuccinimide, N-bromosuccinimide, etc.), or the like.

The reaction is usually carried out in a solvent such as tetrahydrofuran, dioxane, toluene, dichloromethane, 1,2-dichloroethane, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide, or any other organic solvent which does not adversely affect the reaction, or a mixture thereof.

Process 8

The compound (Ij) or a salt thereof can be prepared by subjecting the compound (Ih) or a salt thereof to coupling reaction with the compound (V) or a salt thereof.

This reaction can be carried out in the same manner as the aforementioned coupling reaction in Process 1, and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process 1.

Process A

The compound (VII) or a salt thereof can be prepared by subjecting the compound (VI) or a salt thereof to hydrolysis using an acid (exemplified by Step 1). This reaction can be carried out in the same manner as the aforementioned hydrolysis using an acid in Process 2, and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process 2.

And the object compound (VIII) can be prepared by subjecting the compound (VII) or a salt thereof to the alkylation with the compound (IV) or a salt thereof (exemplified by Step 2). This reaction can be carried out in the same manner as in the aforementioned Process 3, and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process 3.

Process B

The compound (X) or a salt thereof can be prepared from the acetylation of the compound (IX) (exemplified by

Step 1) by the methods disclosed in Preparation 1 mentioned later or the similar manner thereto.

And the object compound (XI) can be prepared by subjecting the compound (X) to the oxime-formation reaction (exemplified by Step 2) that disclosed in Preparation 2 mentioned later or the similar manners thereto.

Process C

The compound (XII) or a salt thereof can be prepared by reacting the compound (XI) or a salt thereof with aminomalonitrile or a salt thereof.

The present reaction is preferably carried out in the presence of a catalyst such as *p*-toluenesulfonic acid, and the like.

This reaction is usually carried out in a conventional solvent such as water, acetone, dioxane, acetonitrile, 1,2-dimethoxyethane, chloroform, dichloromethane, 1,2-dichloroethane, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, methanol, ethanol, isopropanol, t-butanol, diethyl ether, isopropyl ether, a mixture thereof or any other organic solvent which does not adversely affect the reaction.

The reaction temperature is not critical, and the reaction is usually carried out at ambient temperature, under warming or heating.

This reaction can be carried out by the method

disclosed in Preparation 3 mentioned later or the similar manner thereto.

Process D

The compound (XVI) or a salt thereof can be prepared by subjecting the compound (XIII) or a salt thereof to hydrolysis using an acid.

Process E

The compound (II) or a salt thereof can be prepared by reacting the compound (XV) or a salt thereof with the compound (XVI) or a salt thereof.

This reaction is usually carried out in a conventional solvent such as acetone, dioxane, acetonitrile, 1,2-dimethoxyethane, chloroform, dichloromethane, 1,2-dichloroethane, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, diethyl ether, isopropyl ether, a mixture thereof or any other organic solvent which does not adversely affect the reaction.

This reaction can be carried out by the method disclosed in Preparation 4 mentioned later or the similar manner thereto.

Above processes, all starting materials and product compounds may be salts. The compounds of above processes can be converted to salts according to a conventional method.

The object compound (I) of the present invention is an adenosine antagonist and possesses the various pharmacological actions as stated before.

In order to show the usefulness of the compound (I) of the present invention, the pharmacological test result of the representative compound of the present invention is shown in the following.

Test 1 : Adenosine antagonistic activity

[I] Test method

The adenosine antagonistic activity [Ki(nM)] of the test compound was examined by radioligand binding techniques using 8-cyclopentyl-1,3-dipropylxanthine, [dipropyl-2,3-^{3}H(N)] ([^{3}H]DPCPX, 4.5nM) for human A_1 receptor and [^{3}H]CGS 21680 (20nM) for human A_{2a} receptor.

[II] Test compound

3-Amino-6-(1-ethyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide (Example 4)

3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile (Example 11)

3-Amino-5-(3,4-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile (Example 39)

3-Amino-N-(cyanomethyl)-6-(1-isopropyl-6-oxo-

1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide (Example 46)

5-[5-amino-6-(hydroxymethyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone (Example 47)

3-Amino-N-(2-hydroxyethyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide (Example 49)

5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-3-bromo-1-isopropyl-2(1*H*)-pyridone (Example 53)

5-[5-Amino-3-(2-thienyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone (Example 115)

5-[5-Amino-3-(3,5-difluorophenyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone (Example 129)

5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (Example 141)

5-[5-Amino-6-(2-furyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone (Example 144)

5-(5-amino-6-phenoxy-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (Example 151)

[III] Test result

Table 1

Test compound (Example No.)	Adenosine receptor binding (Ki:nM)	
	A_1	A_{2a}
4	5.09	2.34
11	22.47	2.35
39	23.99	6.52
46	5.25	1.49
47	22.27	7.52
49	6.07	1.69
53	0.93	0.91
115	4.89	0.84
129	10.71	3.90
141	0.61	0.23
144	1.78	0.54
151	1.57	0.32

Test 2 : Anticatalepsy activity in Mouse

[I] Test method

The test compound (3.2mg/kg) was administered orally with ddY mice(n=7). Then, haloperidol (0.32mg/kg) was injected intraperitoneally 30 min. after the

administration of the compound. Thirty min. after the injection, the cataleptic responses of mice were measured. The forelimbs of each mouse were placed on a 3 cm high, 3 mm wide horizontal bar, and the duration of cataleptic posture was measured for up to 30 sec.

[II] Test compound

3-Amino-6-(1-ethyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide (Example 4)

3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile (Example 11)

3-Amino-5-(3,4-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile (Example 39)

3-Amino-N-(cyanomethyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide (Example 46)

5-[5-amino-6-(hydroxymethyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone (Example 47)

3-Amino-N-(2-hydroxyethyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide (Example 49)

5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-3-bromo-1-isopropyl-2(1*H*)-pyridone (Example 53)

5-[5-Amino-3-(2-thienyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone (Example 115)

5-[5-Amino-3-(3,5-difluorophenyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone (Example 129)

5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (Example 141)

5-[5-Amino-6-(2-furyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone (Example 144)

5-(5-amino-6-phenoxy-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (Example 151)

[III] Test result

Table 2

Test compound (Example No.)	Manifestation rate of Catalepsy (number of mouse)
4	0/7
11	0/7
39	0/7
46	0/7
47	1/7
49	1/7
53	0/7
115	0/7
129	0/7
141	0/7
144	0/7
151	0/7

The pyrazine compound (I) and a salt thereof of this invention are useful as adenosine antagonists (especially, A_1 receptor and A_2 (particularly A_{2a}) receptor dual antagonists) and for the prevention and/or the treatment of depression, dementia (e.g. Alzheimer's disease, cerebrovascular dementia, dementia accompanying

Parkinson's disease, etc.), Parkinson's disease, anxiety, pain, cerebrovascular disease, heart failure, hypertension, circulatory insufficiency, post-resuscitation, asystole, bradyarrhythmia, electro-mechanical dissociation, hemodynamic collapse, SIRS (systemic inflammatory response syndrome), multiple organ failure, renal failure (renal insufficiency), renal toxicity, nephrosis, nephritis, edema, obesity, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, ulcer, pancreatitis, Meniere's syndrome, anemia, dialysis-induced hypotension, constipation, ischemic bowel disease, ileus, myocardial infarction, thrombosis, obstruction, arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient ischemic attack, angina pectoris, and the like.

Adenosine antagonists can be useful for Parkinson's disease by co-administrating with L-3,4-dihidroxy-phenylalanine(L-DOPA), which is the most popular drug for Parkinson's disease(R. Grondin et al., *Neurology*, **52**, 1673 (1999)). So the combination use of the pyrazine compound (I) and a salt thereof of this invention with L-DOPA may be also useful for treatment and/or prevention of Parkinson's disease with decreasing or reducing the side effect such as the onset of dyskinesia eliciting by the long-team application of L-DOPA, and so

on.

Further, in view of the field using these compounds for as a medicament, these compounds should be durable to some degree. And the duration time of the pyrazine compound (I) or a salt thereof of this invention are expected to be long-lasting.

The pharmaceutical composition of this invention can be used in the form of a pharmaceutical preparation, for example, in a solid, semisolid or liquid form, which contains the pyrazine compound (I) or a pharmaceutically acceptable salt thereof as an active ingredient in admixture with an organic or inorganic carrier or excipient suitable for rectal, pulmonary (nasal or buccal inhalation), nasal, ocular, external (topical), oral or parenteral (including subcutaneous, intravenous and intramuscular) administrations or insufflation. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, troches, capsules, suppositories, creams, ointments, aerosols, powders for insufflation, solutions, emulsions, suspensions, and any other form suitable for use. In addition, auxiliary, stabilizing agents, thickening agents, coloring agents and perfumes may be used where necessary. The pyrazine compound (I) or a pharmaceutically acceptable salt thereof is included in a pharmaceutical composition

in an amount sufficient to produce the desired aforesaid pharmaceutical effect upon the process or condition of diseases.

For applying the composition to a human being or an animal, it is preferable to apply it by intravenous, intramuscular, pulmonary or oral administration, or insufflation. While the dosage of therapeutically effective amount of the pyrazine compound (I) varies depending on the age and condition of each individual patient to be treated, in the case of intravenous administration, a daily dose of 0.01 - 100 mg of the pyrazine compound (I) per kg weight of a human being or an animal, in the case of intramuscular administration, a daily dose of 0.1 - 100 mg of the pyrazine compound (I) per kg weight of a human being or an animal, and in case of oral administration, a daily dose of 0.5 - 100 mg of the pyrazine compound (I) per kg weight of a human being or an animal is generally given for the prevention and/or treatment of the aforesaid diseases.

The following preparations and examples are given for the purpose of illustrating the present invention in more detail.

The abbreviations, symbols and terms used in the preparations and examples have the following meanings.

AcOH	acetic acid
$CHCl_3$	chloroform
CH_2Cl_2	dichloromethane
DME	1,2-dimethoxyethane
DMF	N,N-dimethylformamide
DMSO	dimethyl sulfoxide
EtOAc	ethyl acetate
EtOH	ethanol
IPA	isopropyl alcohol
IPE	isopropyl ether
MeOH	methanol
MeCN	acetonitrile
NMP	N-methylpyrrolidone
THF	tetrahydrofuran
HCl	hydrochloric acid
NEt_3	triethylamine
t-BuOK	potassium tert-butoxide
K_2CO_3	potassium carbonate
$MgSO_4$	magnesium sulfate

NaOAc	sodium acetate
Na_2CO_3	sodium carbonate
NaH	sodium hydride
$NaHCO_3$	sodium bicarbonate
NaOH	sodium hydroxide
EtI	ethyl iodide
MeI	methyl iodide
n-PrBr	*n*-propyl bromide
i-PrI	isopropyl iodide
CuI	cuprous iodide (copper(I) iodide)
$PdCl_2(PPh_3)_2$	dichlorobis(triphenylphosphine)-palladium(II)
$Pd(OAc)_2$	palladium(II) acetate
$Pd(PPh_3)_4$	tetrakis(triphenylphosphine)-palladium(II)
aq.	aqueous
conc.	concentrated
sat.	saturated

Preparation 1

2-Methoxybromopyridine (25 g) and *n*-butyl vinyl ether (66.6 g) were dissolved in DMF (250 ml). To the solution were added 1,3-bis(diphenylphosphino)propane (3.62 g) and $Pd(OAc)_2$ (896 mg) and *aq.* K_2CO_3 under nitrogen atmosphere. The reaction mixture was stirred for 2 hours

at 100-120°C. The mixture was cooled to 25°C. To the solution was added 1*N aq.* HCl (625 ml). The solution was stirred for 1 hour at 25-30°C. The solution was portioned to EtOAc and water. The organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic solution was washed with water and brine, and dried over $MgSO_4$. Evaporation of solvent in vacuo gave oily residue. The residue was purified by chromatography on silica gel (EtOAc : *n*-Hexane=1 : 5, v/v) to give 2-methoxy-5-acetylpyridine as a solid (12.14 g).

^{1}H-NMR(DMSO-d_6 δ) : 2.56 (3H, s), 3.95 (3H, s), 6.92 (1H, d, J=8.4 Hz), 8.17 (1H, dd, J=2.4, 8.4 Hz), 8.30 (1H, d, J=2.4 Hz)

MS(ESI$^+$) : 152$[M+H]^+$

Preparation 2

2-Methoxy-5-acetylpyridine (12.1 g) and t-butyl nitrite (9.92 g) were dissolved in THF (120 ml). The solution was cooled at 0-5°C. To the solution was added *t*-BuOK (10.8 g) at 5-25°C. The reaction mixture was stirred at 25°C for 2 hours. To the mixture was added 1*N* HCl (105 ml). The solution was portioned to EtOAc and water. The organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic solution was washed with 10% *aq.* NaOAc and brine successively, dried over $MgSO_4$. Evaporation of solvent in vacuo gave solid residue.

The residue was pulverized with IPE (150 ml). The precipitated crystals were collected by filtration, to give (1E)-(6-methoxy-3-pyridyl)(oxo)acetaldehyde oxime as a solid (5.45 g) (anti, syn mixture (anti : syn=1:1)).

Evaporation of solvent in the filtrate gave a residue. The residue was pulverized with IPE. The precipitated crystals were collected by filtration, to give (1*E*)-(6-methoxy-3-pyridyl)(oxo) acetaldehyde oxime as a solid (2.5 g) (anti, syn mixture (anti : syn=1:1)).

anti form

^{1}H-NMR(DMSO-d_6 δ) : 3.95 (3H, s), 6.95 (1H, d, J=8.4 Hz), 8.00 (1H, s), 8.23 (1H, dd, J=2.4, 8.4 Hz), 8.85 (1H, d, J=2.4 Hz), 12.7 (1H, s)

MS(ESI$^+$) : 181[M+H]$^+$, 203[M+Na]$^+$

syn form

^{1}H-NMR(DMSO-d_6 δ) : 3.96 (3H, s), 7.00 (1H, d, J=8.4 Hz), 7.59 (1H, s), 8.09 (1H, dd, J=2.4, 8.4 Hz), 8.64 (1H, d, J=2.4 Hz), 11.8 (1H, s),

MS(ESI$^+$) : 181[M+H]$^+$, 203[M+Na]$^+$

Preparation 3

(1*E*)-(6-Methoxy-3-pyridyl)(oxo)acetaldehyde oxime (5.4 g) and aminomalonitrile *p*-toluenesulfonate (7.6 g) were suspended in 2-propanol (108 ml) and stirred at 25°C. To the mixture was added *p*-toluenesulfonic acid (5.71 g). The mixture was heated at 50°C for 2 hours, then at ambient

temperature for 1 hour. The above reaction mixture was concentrated in vacuo. To the concentrated solution was added *sat. aq.* NaOAc. Crystals were precipitated. The suspension was stirred at 20°C for 15 hours. The crystals were collected by filtration, and dried in vacuo to give 3-amino-6-(6-methoxy-3-pyridyl)-2-pyrazinecarbonitrile 4-oxide as powder (6.65 g).

^{1}H-NMR(DMSO-d_6, δ) : 3.90 (3H, s), 6.92 (1H, d, J=8.6 Hz), 8.06 (2H, brs), 8.23 (1H, dd, J=2.4, 8.6 Hz), 8.74 (1H, d, J=2.4 Hz), 9.21 (1H, s)

MS(ESI$^+$) : 244[M+H]$^+$,

IR(KBr) : 3386, 3186, 2238, 1639, 1610, 1489, 1189 cm^{-1}

Preparation 4

3-Amino-6-(6-methoxy-3-pyridyl)-2-pyrazinecarbonitrile 4-oxide (6.65 g) was dissolved in DMF (133 ml). To the solution was added phosphorus oxychloride (12.6 g) at 25°C. The mixture was stirred at ambient temperature for 2 hours. To the mixture was added water (520 ml). The solution was stirred at 20-25°C for 15 hours. The precipitated crystals were collected by filtration and dried in vacuo, to give 3-amino-5-chloro-6-(6-methoxy-3-pyridyl)-2-pyrazinecarbonitrile as powder (4.6 g). The filtrate was extracted with EtOAc. The organic solution was washed with brine, dried over $MgSO_4$. Evaporation of solvent in vacuo gave oily residue. The

residue was purified by chromatography on silica gel (EtOAc : *n*-Hexane=1 : 1, v/v) to give 3-amino-5-chloro-6-(6-methoxy-3-pyridyl)-2-pyrazinecarbonitrile as powder (1.0 g).

^{1}H-NMR(DMSO-d_6 δ) : 3.93 (3H, s), 6.92 (1H, d, J=8.6 Hz), 7.88 (2H, s), 7.95 (1H, dd, J=2.4, 8.6 Hz), 8.43 (1H, d, J=2.4 Hz)

MS(ESI$^+$) : 262[M+H]$^+$, 284[M+Na]$^+$

IR(KBr) : 3384, 3187, 2227, 1656, 1610, 1475, 1209 cm^{-1}

Preparation 5

2-Methoxy-5-bromo-pyridine (615 g) was dissolved in 6*N* HCl (3 l). The solution was heated at 99-105°C. The mixture was refluxed and stirred for 5 hours. The above reaction mixture was cooled to 5°C. The pH of the solution was adjusted to 6.5 with 10% *aq*. NaOH. The precipitated crystal was collected by filtration and washed with water (500 ml), and dried in vacuo, to give 5-bromo-2(1*H*)-pyridone (570 g) as crystal.

^{1}H-NMR(DMSO-d_6 δ) : 6.36 (1H, d, J=9.8 Hz), 7.55 (1H, dd, J=2.8, 9.8 Hz), 7.69 (1H, d, J=2.4 Hz), 11.7 (1H, s)

MS(ESI$^+$) : 196 and 198[M+Na]$^+$

Preparation 6

t-BuOK (32.2 g) was added to the suspension of 5-bromo-2(1*H*)-pyridone (50 g) in DME (500 ml). The mixture was stirred for 30 minutes. To the mixture was added K_2CO_3

(27.8 g) and 2-iodopropane (81.6 g). The reaction mixture was refluxed with stirring for 3 hours. The above mixture was cooled to 20-25°C. The precipitated salt was removed by filtration and washed with DME (100 ml). Evaporation of solvent in vacuo gave solidly residue. The residue was dissolved in $CHCl_3$ (150 ml). The solution was washed with 0.1*N* HCl and brine, and dried over $MgSO_4$. Evaporation of solvent in vacuo gave solidly residue. To the residue was added *n*-hexane (150 ml) to pulverize the residue. The precipitate was collected by filtration and dried in vacuo to give 5-bromo-1-isopropyl-2(1*H*)- pyridone (41.2 g).

^{1}H-NMR(DMSO-d_6 δ) : 1.29 (6H, d, J=6.8 Hz), 4.99 (1H, m), 6.36 (1H, d, J=9.6 Hz), 7.48 (1H, dd, J=2.4, 9.6 Hz), 7.96 (1H, d, J=2.4 Hz)

MS(ESI$^+$) : 216 and 218$[M+H]^+$, 238 and 240$[M+Na]^+$

Preparation 7

5-Bromo-1-isopropyl-2(1*H*)-pyridone (50 g) was dissolved in *n*-butyl vinyl ether (250 ml). To the solution were added 1,3-bis(diphenylphosphino)propane (6.3 g) and powdered K_2CO_3 (38.2 g) and $Pd(OAc)_2$ (1.56 g) at 25°C. The mixture was heated at 90-95°C with stirring for 8 hours. The reaction mixture was cooled to 25-30°C. To the cooled mixture was added $CHCl_3$ (125 ml). The precipitated salt was removed by filtration and washed with $CHCl_3$ (125 ml). Evaporation of solvent in the filtrate in vacuo gave oily

residue. The residue was dissolved in $CHCl_3$ (125 ml). To the solution was added 1*N* HCl (125 ml). The reaction mixture was stirred at 25-30°C for 1 hour. The organic layer was separated. The aqueous layer was extracted with $CHCl_3$ (100 ml). The combined organic layer was washed with 10% *aq.* $NaHCO_3$ (50 ml) and dried over $MgSO_4$ (25 g) and silica gel (25 g). $MgSO_4$ and silica gel were removed by filtration and washed with $CHCl_3$. Evaporation of solvent in the filtrate in vacuo gave oily residue, which was crystallized from *n*-hexane (500 ml). The crystal was collected by filtration and dried in vacuo at 40°C, to give 5-acetyl-1-isopropyl-2(1*H*)-pyridone (32.35 g).

^{1}H-NMR(DMSO-d_6 δ) : 1.37 (6H, d, J=6.8 Hz), 2.47 (3H, s), 5.02 (1H, m), 6.44 (1H, d, J=9.6 Hz), 7.82 (1H, dd, J=2.6, 9.6 Hz), 8.41 (1H, d, J=2.6 Hz)

MS(ESI$^+$) : 180[M+H]$^+$, 202[M+Na]$^+$

Preparation 8

5-Acetyl-1-isopropyl-2(1*H*)-pyridone was dissolved in CH_2Cl_2 (300 ml). The solution was cooled to -30~-25°C. To the cooled solution were added 4*N* hydrogen chloride in dioxane (55.3 ml) and *t*-butyl nitrite (10.4 g) at -30~-25°C. The temperature of the reaction mixture was raised to 20-25°C. The mixture was stirred at the same temperature for 3 hours. The precipitated crystal was collected by filtration, and dried in the air at ambient temperature,

to give (1*E*)-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)(oxo)acetaldehyde oxime (14.0 g).

^{1}H-NMR(DMSO-d_6 δ) : 1.35 (6H, d, J=6.8 Hz), 5.02 (1H, m), 6.47 (1H, d, J=9.6 Hz), 7.89 (1H, dd, J=2.4, 9.6 Hz), 8.00 (1H, s), 8.69 (1H, d, J=2.4 Hz), 12.65 (1H, brs)

MS(ESI$^+$) : 209[M+H]$^+$, 231[M+Na]$^+$

IR(KBr) : 3129, 1660, 1617, 1529, 1018 cm^{-1}

Preparation 9

The mixture of (1*E*)-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)(oxo)acetaldehyde oxime (14 g) and aminomalonitrile *p*-toluenesulfonate (17 g) and IPA (210 ml) was heated at 75-80°C and stirred for 2 hours at the same temperature. The reaction mixture was cooled to 0-5°C and stirred for 2 hours. The precipitate was collected by filtration, and dried in vacuo, to give 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile 4-oxide (9.2 g).

^{1}H-NMR(DMSO-d_6 δ) : 1.36 (6H, d, J=6.8 Hz), 5.09 (1H, m), 6.48 (1H, d, J=9.6 Hz), 7.92-7.99 (3H, m), 8.28 (1H, d, J=2.6 Hz), 9.25 (1H, s)

MS(ESI$^+$) : 293[M+Na]$^+$

IR(KBr) : 3122, 2200, 1656, 1598, 1531, 1174 cm^{-1}

Preparation 10

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile 4-oxide (9 g) was

dissolved in 25% hydrogen bromide solution of AcOH (90 ml) at 20-25°C. The reaction mixture was stirred for 2 hours at ambient temperature. To the reaction mixture was added dioxane (180 ml). The suspension was stirred for 2 hours at ambient temperature. The precipitate was collected by filtration and washed with dioxane, and dried in the air at ambient temperature. The above powder was suspended in water (90 ml). The pH of the suspension was adjusted to 8-8.5 with 1*N* NaOH (70 ml). The suspension was stirred at ambient temperature. The precipitate was collected by filtration and washed with water, and dried in vacuo at 50°C, to give 3-amino- 6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide 4-oxide (8.80 g).

^{1}H-NMR(DMSO-d_6 δ) : 1.39 (6H, d, J=6.8 Hz), 5.10 (1H, m), 6.46 (1H, d, J=9.4 Hz), 7.88 (2H, s), 7.89 (1H, s), 8.32 (1H, dd, J=2.4, 9.4 Hz), 8.41 (1H, d, J=2.4 Hz), 8.51 (1H, s), 9.15 (1H, s)

MS(ESI$^+$) : 312[M+Na]$^+$

IR(KBr) : 3440, 1660, 1596, 1554, 1186 cm^{-1}

Preparation 11

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide 4-oxide (8 g) was dissolved in DMF (80 ml). The solution was cooled to -30°C. To the cooled solution was added phosphoryl chloride (12.7 g) dropwise at -30~-40°C. After addition of phosphoryl

chloride, the temperature of the reaction mixture was raised to -10~-5°C. The mixture was stirred at -10~-5°C for 1 hour. To the reaction mixture was added water (400 ml). The suspension was stirred at 30-35°C for 15 hours. The pH of the suspension was adjusted to 4.5. The suspension was cooled to 0-5°C and stirred at the same temperature for 2 hours. The precipitate was collected by filtration and washed with water, and dried in vacuo at 40-50°C, to give 3-amino-5-chloro-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide (7.1 g).

^{1}H-NMR(DMSO-d_6 δ) : 1.34 (6H, d, J=7.0 Hz), 5.09 (1H, m), 6.44 (1H, d, J=9.4 Hz), 7.74 (1H, s), 7.85 (1H, dd, J=2.4, 9.4 Hz), 7.85 (2H, s), 8.13 (1H, d, J=2.4 Hz), 8.13 (1H, s)

MS(ESI$^+$) : 330 and 332$[M+Na]^+$

IR(KBr) : 3284, 1673, 1604, 1461, 1187 cm^{-1}

Preparation 12

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide 4-oxide (29.1 g) was dissolved in DMF (290 ml). The solution was cooled to -30°C. To the cooled solution was added phosphoryl chloride (46.3 g) dropwise at -30~-40°C. After addition of phosphoryl chloride, the temperature of the reaction mixture was raised to 40-45°C. The mixture was stirred at 40-45°C for 1 hour. To the reaction mixture was added water (1160 ml).

The suspension was stirred at 30-35°C for 15 hours. The pH of the suspension was adjusted to 7 with 12% aq. NaOH (400 ml). The suspension was cooled to 0-5°C and stirred at the same temperature for 2 hours. The precipitate was collected by filtration and washed with water, and dried in vacuo at 40-50°C, to give 3-amino-5-chloro-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile (17.2 g).

^{1}H-NMR(DMSO-d_6 δ) : 1.34 (6H, d, J=7.0 Hz), 5.09 (1H, m), 6.44 (1H, d, J=9.4 Hz), 7.74 (1H, s), 7.85 (1H, dd, J=2.4, 9.4 Hz), 7.85 (2H, s), 8.13 (1H, d, J=2.4 Hz), 8.13 (1H, s)

MS(ESI$^+$) : 330[M+Na]$^+$

IR(KBr) : 3291, 1662, 1600, 1465, 1182 cm^{-1}

Preparation 13

To a solution of 1-(diphenylmethyl)-3-azetidinol hydrochloride (5.0 g) in DMF (25 ml), was added sodium hydride under ice-bath cooling. After 10 minute stirring at the same temperature, the mixture was allowed to warm to 25°C and then stirred for 15 hours. EtOAc (500 ml) and water (200 ml) were poured into the mixture. The organic layer was separated, washed with water and brine, and dried over $MgSO_4$. The solvent was removed under reduced pressure. The residue was purified by column chromatography (silica gel; 200 ml, toluene : EtOAc=15 : 1 - 8 : 1) to give 1-(diphenylmethyl)-3-methoxyazetidine (3.41 g).

^{1}H-NMR(DMSO-d_6 δ) : 2.7-2.9 (2H, m), 3.12 (3H, s), 3.3-3.5 (2H, m), 3.99 (1H, m), 4.40 (1H, s), 7.1-7.4 (6H, m), 7.3-7.5 (4H, m)

MS(ESI$^+$) : 254[M+H]$^+$

Preparation 14

To a solution of 1-(diphenylmethyl)-3-methoxy-azetidine (3.4 g) in MeOH (35 ml), was added 20% palladium hydroxide on carbon (0.7 g). And then the mixture was stirred under hydrogen atmosphere for 2.5 hours. 1*N* HCl (20 ml) was added to the mixture and the catalyst was removed by filtration and washed with 1*N* HCl. The solvent was removed under reduced pressure. Water and EtOAc were poured into the residue, and the aqueous layer was separated, washed with EtOAc. The solvent was removed under reduced pressure and the residue was azeotroped with EtOH and dried in vacuo. *n*-Hexane was poured into the residue and a crystal was isolated by filtration, washed with *n*-hexane, and dried in vacuo to give 3-methoxyazetidine hydrochloride (1.58 g).

^{1}H-NMR(DMSO-d_6 δ) : 3.21 (3H, s), 3.6-3.9 (2H, m), 4.0-4.4 (3H, m)

MS(ESI$^+$) : 88[M+H]$^+$ (free form)

Preparation 15

The mixture of 5-bromo-2(1*H*)-pyridone (200 g) and MeI (324 g) and K_2CO_3 (318 g) in DME (2 l) was heated at 80°C with stirring for 2 hours. The above mixture was cooled to

room temperature. The precipitated salt was removed by filtration and washed with DME. Evaporation of solvent in the filtrate in vacuo gave oily residue. The residue was portioned to EtOAc and water. The organic layer was separated. Aqueous layer was extracted with EtOAc twice. The combined organic solution was dried over $MgSO_4$. Evaporation of solvent in vacuo gave crystal residue. The residue was pulverized with IPE and *n*-hexane (1 : 3, 1000 ml). The precipitate was collected by filtration and dried in vacuo to give 5-bromo-1-methyl- 2(1*H*)-pyridone as white powder (182.5 g).

^{1}H-NMR(DMSO-d_6 δ) : 3.40 (3H, s), 6.36 (1H, d, J=9.6 Hz), 7.51 (1H, dd, J=2.8, 9.6 Hz), 8.03 (1H, d, J=2.8 Hz)

MS(ESI$^+$) : 210 and 212[M+Na]$^+$

Preparation 16

5-Bromo-1-methyl-2(1*H*)-pyridone (150 g) was dissolved in DMF (1500 ml). To the solution were added 1,3-bis(diphenylphosphino)propane (21.7 g), *n*-butyl vinyl ether (400 g), and 3*M aq*. potassium carbonate (262.5 ml) and $Pd(OAc)_2$ (10.2 g). The mixture was heated at 80°C and stirred for 3 hours at the same temperature. The reaction mixture was cooled to 25-30°C and poured to 1*N* HCl (1485 ml). The mixture was stirred for 2 hours at 30-40°C. The solution was extracted with EtOAc (1500 ml, three times). The aqueous layer was extracted with CH_2Cl_2 (1000 ml, three

times). The collected organic solution was dried over $MgSO_4$. Evaporation of solvent gave solidly residue, which was pulverized with IPA (150 ml) and IPE (1500 ml). The suspension was stood in the refrigerator overnight. The precipitate was collected by filtration, dried in vacuo, to give 5-acetyl-1-methyl-2(1*H*)-pyridone as white powder (128 g).

^{1}H-NMR(DMSO-d_6 δ) : 2.41 (3H, s), 3.52 (3H, s), 6.42 (1H, d, J=9.6 Hz), 7.84 (1H, dd, J=2.4, 9.6 Hz), 8.66 (1H, d, J=2.4 Hz)

MS(ESI$^+$) : 152[M+H]$^+$, 174[M+Na]$^+$

Preparation 17

(1*E*)-(1-Methyl-6-oxo-1,6-dihydro-3-pyridyl)(oxo) acetaldehyde oxime

The title compound was obtained in a similar manner to that of Preparation 8.

^{1}H-NMR(DMSO-d_6 δ) : 3.57 (3H, s), 6.47 (1H, d, J=9.6 Hz), 7.93 (1H, dd, J=2.4, 9.6 Hz), 8.03 (1H, s), 8.76 (1H, d, J=2.4 Hz), 12.62 (1H, s)

MS(ESI$^+$) : 203[M+Na]$^+$

Preparation 18

3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile 4-oxide

The title compound was obtained in a similar manner to that of Preparation 9.

^{1}H-NMR(DMSO-d_6 δ) : 3.50 (3H, s), 6.47 (1H, d, J=9.6 Hz), 7.96 (2H, s), 7.96-8.02 (IH, m), 8.43 (1H, d, J=2.4 Hz), 9.04 (1H, s)

MS(ESI$^+$) : 244[M+Na]$^+$

Preparation 19

3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile 4-oxide (97 g) was added to 25% hydrogen bromide solution of AcOH (700 ml) at 25-30°C. The mixture was stirred for 2 hours at ambient temperature. To the mixture was added 12% *aq.* NaOH (2100 ml) and water (1000 ml). The mixture was stirred overnight at the refrigerator. The resultant precipitated crystals were collected by filtration, and washed with water, and dried in vacuo, to give 3-amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide 4-oxide as powder (52 g).

^{1}H-NMR(DMSO-d_6 δ) : 3.52 (3H, s), 6.45 (1H, d, J=9.6 Hz), 7.82 (2H, s), 7.92 (1H, s), 8.26(1H, dd, J=2.6, 9.6 Hz), 8.54 (1H, s), 8.72 (1H, d, J=2.6 Hz), 8.97 (1H, s)

MS(ESI$^+$) : 262[M+H]$^+$, 284[M+Na]$^+$

Preparation 20

3-Amino-5-chloro-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile

The title compound was obtained in a similar manner to that of Preparation 12.

^{1}H-NMR(DMSO-d_6 δ) : 3.25 (3H, s), 6.45 (1H, d, J=9.4 Hz),

7.70 (1H, dd, J=2.6, 9.4 Hz), 7.83 (2H, s), 8.06 (1H, d, J=2.6 Hz)

MS(ESI$^+$) : 262 and 263[M+H]$^+$, 284 and 286[M+Na]$^+$

Preparation 21

To a suspension of 3-amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide 4-oxide (1.0 g) in DMF was added phosphoric trichloride (1.07 ml) at -40°C for 20 minutes. This reaction mixture was warmed to -10°C and stirred for 1 hour. To this solution was added water (40 ml) and stirred at 40°C for 14 hours. The pH of the resulting suspension was adjusted to 4.5 with 30% The pH of the aqueous mixture was adjusted to 6-7 with 12% *aq.* NaOH. The precipitate was collected by filtration and washed with water to give 3-amino-5-chloro-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide (263 mg) as a yellow powder.

MS(ESI$^+$) : 280[M+H]$^+$

Example 1

3-Amino-5-chloro-6-(6-methoxy-3-pyridyl)-2-pyrazinecarbonitrile (1.35 g) was dissolved in dioxane (135 ml). To the solution were added phenylboronic acid (1.89 g) and $Pd(PPh_3)_4$ (179 mg) and Na_2CO_3 (2.19 g) in water (27 ml) at 25°C. The reaction mixture was heated at 80°C for 2 hours, then at ambient temperature for 3 hours. The above mixture was portioned to EtOAc and water. The organic

layer was separated and washed with *aq.* Na_2CO_3 and brine, and dried over $MgSO_4$. Evaporation of solvent in vacuo gave oily residue, which was purified by chromatography on silica gel (EtOAc : *n*-Hexane=1 : 1, v/v) to give 3-amino-6-(6-methoxy-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile as yellow crystal which was crystallized from EtOAc (1.15 g).

^{1}H-NMR(DMSO-d_6 δ) : 3.81 (3H, s), 6.73 (1H, d, J=8.6 Hz), 7.35 (5H, s), 7.51 (2H, s), 7.54 (1H, dd, J=2.4, 8.6 Hz), 7.99 (1H, d, J=2.4 Hz)

MS(ESI$^+$) : 304$[M+H]^+$, 326$[M+Na]^+$

IR(KBr) : 3357, 3183, 2238, 1648, 1598, 1544, 1195 cm^{-1}

m.p. : 201-205°C (IPE)

Example 2

3-Amino-6-(6-methoxy-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile (500 mg) was dissolved in dioxane (10 ml) and *conc.* HCl (5 ml). The solution was stirred at 80°C for 5 hours. The reaction mixture was cooled to 25-30°C and concentrated in vacuo to give a residue. To the residue was added water and 1*N* NaOH to adjust the pH of the aqueous mixture to 6-7. The precipitated crystals were collected by filtration dried in vacuo to give 3-amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide (390 mg).

^{1}H-NMR(DMSO-d_6 δ) : 6.16 (1H, d, J=9.4 Hz), 7.26-7.70 (10H,

m), 8.23 (1H, s), 11.66 (1H, s)

MS(ESI$^+$) : 330[M+Na]$^+$

MS(ESI$^-$) : 306[M-H]$^-$

IR(KBr) : 3309, 1656, 1610, 1544, 1201 cm^{-1}

m.p. : 215-220°C (H_2O)

Example 3

3-Amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide (61.4 mg) was dissolved in DMF (1 ml). To the solution were added 1*M* MeI solution in DMF (0.22 ml) and 0.1*M* *t*-BuOK solution in DMF (2.2 ml). The mixture was stirred at 20-30°C for 2 hours. The reaction mixture was portioned EtOAc and water. The organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic solution was washed with brine and dried over $MgSO_4$. Evaporation of solvent gave oily residue. The above residue was purified by chromatography on silica gel (EtOAc only - EtOAc : MeOH=93 : 7, v/v) to give 3-amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide, which was crystallized from EtOAc (20 mg).

^{1}H-NMR(DMSO-d_6 δ) : 3.45 (3H, s), 6.12 (1H, d, J=9.4 Hz), 6.97 (1H, dd, J=2.4, 9.4 Hz), 7.41-7.62 (8H, m), 8.14 (1H, d, J=2.4 Hz), 8.29 (1H, s)

MS(ESI$^+$) : 344[M+Na]$^+$

IR(KBr) : 3353, 1664, 1599, 1531, 1438 cm^{-1}

m.p. : >250°C (EtOAc)

Example 4

3-Amino-6-(1-ethyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide

The title compound was obtained in a similar manner to that of Example 3.

^{1}H-NMR(DMSO-d_6 δ) : 1.12 (3H, t, J=7.0 Hz), 3.84 (2H, q, J=7.0 Hz), 6.18 (1H, d, J=9.4 Hz), 7.21 (1H, dd, J=2.4, 9.4 Hz), 7.40-7.72 (8H, m), 7.89 (1H, d, J=2.4 Hz), 8.27 (1H, s)

MS(ESI$^+$) : 336$[M+H]^+$, 358$[M+Na]^+$

IR(KBr) : 3154, 1679, 1597, 1535, 1444 cm^{-1}

m.p. : >250°C (EtOAc)

Example 5

3-Amino-6-(6-oxo-1-propyl-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide

The title compound was obtained in a similar manner to that of Preparation 3.

^{1}H-NMR(DMSO-d_6 δ) : 0.77 (3H, t, J=7.4 Hz), 1.52 (2H, m), 3.76 (2H, t, J=7.2 Hz), 6.20 (1H, d, J=9.4 Hz), 7.34-7.47 (8H, m), 7.66-7.72 (2H, m), 8.19 (1H, s)

MS(ESI$^+$) : 350$[M+H]^+$, 372$[M+Na]^+$

IR(KBr) : 3421, 1650, 1571, 1515, 1417cm^{-1}

m.p. : >250°C (EtOAc)

Example 6

3-Amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide (92.1 mg) was dissolved in DMF (1 ml). To the solution were added 1*M* *i*-PrI solution in DMF (0.33 ml) and 0.1*M* *t*-BuOK solution in DMF (3.3 ml). The mixture was stirred at 20-30°C for 2 hours. The reaction mixture was portioned EtOAc and water. The organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic solution was washed with brine and dried over $MgSO_4$. Evaporation of solvent gave oily residue. The above residue was purified by chromatography on silica gel (EtOAc only - EtOAc : MeOH=96 : 4, v/v) to give 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide (18 mg) and 3-amino-6-(6-isopropoxy-3-pyridyl)-5-phenyl-2-pyrazine-carboxamide (42 mg).

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 0.97 (6H, d, J=6.8 Hz), 4.90 (1H, m), 6.20 (1H, d, J=9.4 Hz), 7.34-7.47 (8H, m), 7.66-7.72 (2H, m), 8.19 (1H, s)

MS(ESI$^+$) : 350 $[M+H]^+$, 372 $[M+Na]^+$

IR(KBr) : 3417, 1664, 1591, 1533, 1450 cm^{-1}

m.p. : 240-245°C (EtOAc)

3-Amino-6-(6-isopropoxy-3-pyridyl)-5-phenyl-2-pyrazine-carboxamide

^{1}H-NMR(DMSO-d_6 δ) : 1.26 (6H, d, J=6.8 Hz), 5.20 (1H, m), 6.60 (1H, d, J=8.6 Hz), 7.42 (5H, s), 7.60-7.67 (3H, m), 8.17 (2H, s)

MS(ESI$^+$) : 350 $[M+H]^+$, 372 $[M+Na]^+$

IR(KBr) : 3471, 1683, 1656, 1600, 1488 cm^{-1}

Example 7

3-Amino-6-(6-methoxy-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile (800 mg) was dissolved in dioxane and *conc.* HCl. The solution was stirred at 80°C for 15 hours. Dioxane was evaporated out. The reaction mixture was cooled to room temperature and concentrated in vacuo to give residue. To the residue was added 1*N* NaOH to adjust the pH of the aqueous mixture to 6-7. The crystals were collected by filtration, and dried in vacuo to give 3-amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylic acid as powder (600 mg).

^{1}H-NMR(DMSO-d_6 δ) : 6.18 (1H, d, J=9.4 Hz), 7.25-7.65 (9H, m), 11.8 (2H, brs)

MS(ESI$^-$) : 307$[M-H]^-$

Example 8

3-Amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylic acid (154 mg) was dissolved in DMF(5 ml). To the solution were added EtI (86.1 mg) and *t*-BuOK (61.9 mg). The mixture was stirred at 20-30°C for 2 hours. The reaction mixture was portioned EtOAc and water. The

organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic solution was washed with brine and dried over $MgSO_4$. Evaporation of solvent gave oily residue. The above residue was purified by chromatography on silica gel (EtOAc only - EtOAc : MeOH=95 : 5, v/v) to give ethyl 3-amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylate (84 mg) and ethyl 3-amino-6-(1-ethyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylate (28 mg).

Ethyl 3-amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylate

^{1}H-NMR(DMSO-d_6 δ) : 1.34 (3H, t, J=7.0 Hz), 4.37 (2H, q, J=7.0 Hz), 6.23 (1H, d, J=9.4 Hz), 7.19 (1H, d, J=2.4 Hz), 7.25 (1H, dd, J=2.4, 9.4 Hz), 7.40-7.52 (5H, m)

MS(ESI$^+$) : 359[M+Na]$^+$

IR(KBr) : 3400, 1697, 1614, 1434, 1130 cm^{-1}

m.p. : 230-238°C (EtOAc)

Ethyl 3-amino-6-(1-ethyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylate

^{1}H-NMR(DMSO-d_6 δ) : 1.00 (3H, t, J=7.0 Hz), 1.34 (3H, t, J=7.0 Hz), 3.76 (2H, q, J=7.0 Hz), 4.37 (2H, q, J=7.0 Hz), 6.32 (1H, d, J=9.4 Hz), 7.32 (1H, dd, J=2.6, 9.4 Hz), 7.36-7.5 (8H, m)

MS(ESI$^+$) : 365[M+H]$^+$, 387[M+Na]$^+$

IR(KBr) : 3400, 1662, 1600, 1440, 1122 cm^{-1}

m.p. : 175-179°C (EtOAc)

Example 9

3-Amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylic acid (283 mg) was dissolved in DMF (10 ml). To the solution were added *i*-PrI (172 mg) and *t*-BuOK (114 mg). The mixture was stirred at 20-30°C for 2 hours. The reaction mixture was portioned EtOAc and water. The organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic solution was washed with brine and dried over $MgSO_4$. Evaporation of solvent gave oily residue. The above residue was purified by chromatography on silica gel (EtOAc only - EtOAc : MeOH=96 : 4, v/v) to give isopropyl 3-amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylate as yellow crystal (64mg).

^{1}H-NMR(DMSO-d_6 δ) : 1.35 (6H, d, J=6.2 Hz), 5.20 (1H, m), 6.23 (1H, d, J=9.4Hz), 7.19 (1H, d, J=2.2 Hz), 7.22 (1H, dd, J=2.2, 9.4 Hz), 7.40 (5H, m), 11.6 (1H, s)

MS(ESI$^+$) : 351$[M+H]^+$, 373$[M+Na]^+$

IR(KBr) : 3425, 1666, 1612, 1434, 1101 cm^{-1}

m.p. : 250-256°C (EtOAc)

Example 10

3-Amino-6-(6-methoxy-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile (370 mg) was dissolved in 1,2-dichloroethane (37 ml). To the solution was added 1*M*

boron tribromide solution in CH_2Cl_2 (12.2 ml). The mixture was stirred at 80°C for 24 hours. The mixture was cooled to 20-25°C, and portioned to EtOAc and water. The organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic layer was washed with brine, and dried over $MgSO_4$. Evaporation of solvent in vacuo gave reddish solid residue. The residue was pulverized with water, to give 3-amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile as powder (254 mg).

^{1}H-NMR(DMSO-d_6 δ) : 6.21 (1H, d, J=9.4 Hz), 7.20-7.98 (7H, m), 11.6 (1H, s)

MS(ESI$^+$) : 312[M+Na]$^+$

IR(KBr) : 3326, 2221, 1656, 1610, 1544, 1201 cm^{-1}

m.p. : 243-248°C (H_2O)

Example 11

3-Amino-6-(6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile (58 mg) was dissolved in DMF (1 ml). To the solution were added 1*M* MeI solution in DMF (0.22 ml) and 0.1*M* t-BuOK solution in DMF (2.2 ml). The mixture was stirred at 20-30°C for 2 hours. The reaction mixture was portioned EtOAc and water. The organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic solution was washed with brine and dried over $MgSO_4$. Evaporation of solvent gave oily residue. The above residue was purified by chromatography on silica gel (EtOAc only

- EtOAc : MeOH=93 : 7, v/v) to give 3-amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazine-carbonitrile, which was crystallized from EtOAc (18 mg).

^{1}H-NMR(DMSO-d_6 δ) : 3.40 (3H, s), 6.17 (1H, d, J=9.4 Hz), 6.97 (1H, dd, J=2.6, 9.4 Hz), 7.40-7.50 (7H, m), 7.81 (1H, d, J=2.6 Hz)

MS(ESI$^+$) : 304[M+H]$^+$, 326[M+Na]$^+$

IR(KBr) : 3386, 2221, 1670, 1590, 1542, 1205 cm^{-1}

m.p. : >250°C (EtOAc)

Example 12

3-Amino-6-(1-ethyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile

The title compound was obtained in a similar manner to that of Example 11.

^{1}H-NMR(DMSO-d_6 δ) : 1.03 (3H, t, J=7.0 Hz), 3.79 (2H, q, J=7.0 Hz), 6.25 (1H, d, J=9.4 Hz), 7.19 (1H, dd, J=2.6, 9.4 Hz), 7.44-7.47 (7H, m), 7.58 (1H, d, J=2.6 Hz)

MS(ESI$^+$) : 318[M+H]$^+$, 340[M+Na]$^+$

IR(KBr) : 3180, 2221, 1657, 1587, 1535, 1203 cm^{-1}

m.p. : 193-199°C (IPE)

Example 13

3-Amino-6-(6-oxo-1-propyl-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile (17 mg)

The title compound was obtained in a similar manner to that of Example 11.

^{1}H-NMR(DMSO-d_6 δ) : 0.71 (3H, t, J=7.4 Hz), 1.44 (2H, m), 3.73 (2H, t, J=7.2 Hz), 6.26 (1H, d, J=9.4 Hz), 7.20 (1H, dd, J=2.6, 9.4 Hz), 7.38-7.47 (7H, m), 7.54 (1H, d, J=2.6 Hz)

MS(ESI$^+$) : 332[M+H]$^+$, 354[M+Na]$^+$

IR(KBr) : 3311, 2220, 1658, 1536, 1463, 1201 cm^{-1}

m.p. : 180-183°C (IPE)

Example 14

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile

The title compound was obtained in a similar manner to that of Example 11.

^{1}H-NMR(DMSO-d_6 δ) : 0.94 (6H, d, J=6.8 Hz), 4.85-4.92 (1H, m), 6.35 (1H, d, J=9.4 Hz), 7.28 (1H, d, J=2.4 Hz), 7.38-7.49 (8H, m)

MS(ESI$^+$) : 332[M+H]$^+$, 354[M+Na]$^+$

IR(KBr) : 3426, 2225, 1664, 1621, 15521, 1106 cm^{-1}

m.p. : 204.5°C (95% *aq.*2-propanol)

Example 15

3-Amino-6-(6-methoxy-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile (100 mg) was dissolved in 30% hydrogen bromide solution in AcOH (1 ml). The solution was stirred at 25-30°C for 3 hours. To the solution was added water. The pH of the aqueous mixture was adjusted to 6-7 with 12% *aq.* NaOH. The crystals were precipitated. The

suspension was stirred at 25-30°C for 3 hours, and stood for 10 hours in refrigerator. The crystals was collected by filtration and dried in vacuo, to give 3-amino-6-(6-methoxy-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide (92.5 mg).

^{1}H-NMR(DMSO-d_6 δ) : 3.82 (3H, s), 6.69 (1H, d, J=6.6 Hz), 7.39 (5H, s), 7.64-7.70 (3H, m), 8.17 (2H, s)

MS(ESI$^+$) : 322[M+H]$^+$, 344[M+Na]$^+$

IR(KBr) : 3411, 3276, 1689, 1598,1496,1286 cm^{-1}

m.p. : 208-212°C (H_2O)

The following 24 compounds were obtained in a similar manner to that of Example 1.

Example 16

3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 0.97 (6H, d, J=6.8 Hz), 4.90 (1H, m), 6.32 (1H, d, J=9.4 Hz), 7.34-7.46 (6H, m), 7.66-7.72 (4H, m), 8.19 (1H, s)

MS(ESI$^+$) : 350[M+H]$^+$, 372[M+Na]$^+$

IR(KBr) : 3417, 1664, 1590, 1533, 1450 cm^{-1}

mp : 245°C (IPA-H_2O)

Example 17

3-Amino-5-(2-fluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 0.93 (6H, d, J=6.8 Hz), 4.89 (1H, m),

6.35 (1H, d, J=9.4 Hz), 7.22-7.81 (9H, m), 8.22 (1H, s)

MS(ESI$^+$) : 368[M+H]$^+$, 390[M+Na]$^+$

IR(KBr) : 3367, 1664, 1600, 1446, 1205 cm^{-1}

mp : 251.7°C (IPA-H_2O)

Example 18

3-Amino-5-(3-fluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 1.01 (6H, d, J=6.8 Hz), 4.93 (1H, m), 6.35 (1H, d, J=9.4 Hz), 7.21-7.71 (9H, m), 8.22 (1H, s)

MS(ESI$^+$) : 368[M+H]$^+$, 390[M+Na]$^+$

IR(KBr) : 3394, 1658, 1590, 1533, 1452 cm^{-1}

mp : 258.8°C (IPA-H_2O)

Example 19

3-Amino-5-(4-fluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 0.97 (6H, d, J=6.8 Hz), 4.90 (1H, m), 6.32 (1H, d, J=9.4 Hz), 7.34-7.46 (6H, m), 7.66-7.72 (3H, m), 8.19 (1H, s)

MS(ESI$^+$) : 390[M+Na]$^+$

IR(KBr) : 3293, 1660, 1583, 1450, 1153 cm^{-1}

mp : 235.6°C (IPA-H_2O)

Example 20

3-Amino-5-(2-chlorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 0.90 (6H, m), 4.87 (1H, m), 6.34 (1H,

d, J=9.4 Hz), 7.16 (1H, d, J=2.4 Hz), 7.48-7.68 (6H, m), 7.73 (1H, s), 7.82 (1H, dd, J=2.4, 9.4 Hz), 8.24 (1H, s)

MS(ESI^+) : 384$[M+H]^+$, 406$[M+Na]^+$

IR(KBr) : 3367, 1666, 1604, 1454, 1157 cm^{-1}

mp: 254.5°C (IPA-H_2O)

Example 21

3-Amino-5-(3-chlorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

^1H-NMR(DMSO-d_6 δ) : 1.01 (6H, d, J=6.8 Hz), 4.93 (1H, m), 6.35 (1H, d, J=9.4 Hz), 7.35-7.46 (5H, m), 7.49 (2H, s), 7.57-7.72 (3H, m), 8.21 (1H,s)

MS(ESI^+) : 384$[M+H]^+$, 406$[M+Na]^+$

IR(KBr) : 3396, 1658, 1589, 1452, 1250 cm^{-1}

mp: 232.6°C (IPA-H_2O)

Example 22

3-Amino-5-(4-chlorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

^1H-NMR(DMSO-d_6 δ) : 1.02 (6H, d, J=6.8 Hz), 4.94 (1H, m), 6.34 (1H, d, J=9.4 Hz), 7.40 (1H, d, J=2.4Hz), 7.49 (6H, s), 7.6 5(1H, dd, J=2.4, 9.4 Hz), 7.70 (1H, s), 8.21 (1H, s)

MS(ESI^+) : 406$[M+Na]^+$

IR(KBr) : 3278, 1664, 1587, 1450, 1093 cm^{-1}

mp: 246.2°C (IPA-H_2O)

Example 23

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(2-methoxyphenyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 0.89-1.05 (6H, m), 3.48 (3H, s), 4.88 (1H, m), 6.32 (1H, d, J=9.4 Hz), 6.99-7.13 (2H, m), 7.22 (1H, d, J=2.4 Hz), 7.37-7.65 (2H, m), 7.59 (2H, brs), 7.66 (1H, s), 7.75 (1H, dd, J=2.4, 9.4 Hz), 8.16 (1H, s)

MS(ESI$^+$) : 380[M+H]$^+$, 402[M+Na]$^+$

IR(KBr) : 3259, 1662, 1596, 1452, 1259 cm^{-1}

mp : 263.1°C (IPA-H_2O)

Example 24

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(3-methoxyphenyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 1.01 (6H, d, J=6.8 Hz), 3.71 (3H, s), 4.90 (1H, m), 6.33 (1H, d, J=9.4 Hz), 6.94-7.02 (3H, m), 7.30-7.39 (2H, m), 7.65-7.71 (3H, m), 8.19 (1H, s)

MS(ESI$^+$) : 380[M+H]$^+$, 402[M+Na]$^+$

IR(KBr) : 3442, 1660, 1581, 1444, 1268 cm^{-1}

IR(KBr) : 3442, 1660, 1581, 1444, 1268 cm-1

mp : 192.3°C (IPA-H_2O)

Example 25

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(4-methoxyphenyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 1.05 (6H, d, J=6.8 Hz), 3.77 (3H, s), 4.94 (1H, m), 6.32 (1H, d, J=9.4 Hz), 6.97 (2H, d, J=8.8 Hz), 7.42 (2H, d, J=8.8 Hz), 7.45-7.64 (5H, m), 8.15 (1H,

s)

MS(ESI$^+$) : 380[M+H]$^+$, 402[M+Na]$^+$

IR(KBr) : 3266, 1664, 1600, 1448, 1255 cm^{-1}

mp : 243.9°C (IPA-H_2O)

Example 26

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-[2-(trifluoromethoxy)phenyl]-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 0.90 (6H, m), 4.88 (1H, m), 6.34 (1H, d, J=9.4 Hz),7.20 (1H, d, J=2.4 Hz), 7.34-7.39 (1H, m), 7.54-7.78 (7H, m), 8.24 (1H, s)

MS(ESI$^+$) : 434[M+H]$^+$, 456[M+Na]$^+$

IR(KBr) : 3386, 1662, 1596, 1257, 1162 cm^{-1}

mp : 206.5°C (IPA-H_2O)

Example 27

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-[3-(trifluoromethoxy)phenyl]-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 0.98 (6H, d, J=6.8 Hz), 4.88 (1H, m), 6.35 (1H, d, J=9.4 Hz), 7.37-7.81 (9H, m), 8.22 (1H,s)

MS(ESI$^+$) : 434[M+H]$^+$, 456[M+Na]$^+$

IR(KBr) : 3403, 1660, 1592, 1452, 1263 cm^{-1}

mp : 265.5°C (IPA-H_2O)

Example 28

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-[4-(trifluoromethoxy)phenyl]-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 0.98 (6H, d, J=6.8 Hz), 4.91 (1H, m),

6.37 (1H, d, J=9.4 Hz),7.30 (1H, d, J=2.4Hz), 7.42 (2H, d, J=8.2Hz), 7.58 (2H, d, J=8.2Hz), 7.70 (3H, m), 7.78 (1H, dd, J=2.4, 9.4Hz), 8.21 (1H,s)

MS(ESI$^+$) : 434[M+H]$^+$, 456[M+Na]$^+$

IR(KBr) : 3403, 1660, 1592, 1452, 1263 cm^{-1}

mp : 264.0°C (IPA-H_2O)

Example 29

3-Amino-5-(3,4-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 1.05 (6H, d, J=6.8 Hz), 4.96 (1H, m), 6.35 (1H, d, J=9.2 Hz), 7.28 (1H, d, J=6.4 Hz), 7.46-7.65 (6H, m), 7.71 (1H, s), 8.21 (1H, s)

MS(ESI$^+$) : 386[M+H]$^+$, 408[M+Na]$^+$

IR(KBr) : 3382, 1662, 1602, 1444, 1191 cm^{-1}

mp : 225.8°C (IPA-H_2O)

Example 30

3-Amino-5-(3,5-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 1.05 (6H, d, J=6.8 Hz), 4.95 (1H, m), 6.37 (1H, d, J=9.4 Hz), 7.14-7.37 (3H, m), 7.46 (1H, d, J=2.4Hz), 7.66 (1H, dd, J=2.4,9.4Hz)), 7.73 (3H, m), 8.23 (1H, s)

MS(ESI$^+$) : 408[M+Na]$^+$

IR(KBr) : 3284, 1664, 1587, 1446, 1120 cm^{-1}

mp : 248.8°C (IPA-H_2O)

Example 31

3-Amino-5-(4-cyanophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 0.98 (6H, d, J=6.8 Hz), 4.92 (1H, m), 6.35 (1H, d, J=9.4 Hz), 7.38 (1H, d, J=2.4 Hz), 7.65 (2H, d, J=8.4 Hz), 7.65-7.69 (4H, m), 7.74 (1H, s), 7.90 (1H, d, J=8.4 Hz), 8.24 (1H, s)

MS(ESI$^+$) : 397[M+Na]$^+$

IR(KBr) : 3432, 2223, 1671, 1606, 1450 cm^{-1}

mp : 292°C (IPA-H_2O)

Example 32

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile

^{1}H-NMR(DMSO-d_6 δ) : 0.94 (6H, d, J=6.8 Hz), 4.89 (1H, m), 6.35 (1H, d, J=9.4 Hz), 7.28 (1H, d, J=2.4 Hz), 7.39-7.49 (8H, m)

MS(ESI$^+$) : 332[M+H]$^+$, 354[M+Na]$^+$

IR(KBr) : 3357, 2219, 1652, 1579, 1465, 1203 cm^{-1}

mp : 205.4°C (IPA-H_2O)

Example 33

3-Amino-5-(2-fluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile

^{1}H-NMR(DMSO-d_6 δ) : 0.91 (6H, d, J=6.8 Hz), 4.87 (1H, m), 6.37 (1H, d, J=9.4 Hz), 7.18-7.63 (8H, m)

MS(ESI$^+$) : 350[M+H]$^+$, 372[M+Na]$^+$

IR(KBr) : 3366, 2214, 1615, 1516, 1200 cm^{-1}

mp : 210.6°C (IPA-H_2O)

Example 34

3-Amino-5-(3-fluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile

^{1}H-NMR(DMSO-d_6 δ) : 0.98 (6H, d, J=6.8 Hz), 4.92 (1H, m), 6.37 (1H, d, J=9.4 Hz), 7.22-7.53 (8H, m)

MS(ESI^+) : 350$[M+H]^+$, 372$[M+Na]^+$

IR(KBr) : 3360, 2214, 1660, 1570, 1205 cm^{-1}

mp : 210.6°C (IPA-H_2O)

Example 35

3-Amino-5-(4-fluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile

^{1}H-NMR(DMSO-d_6 δ) : 0.98 (6H, d, J=6.8 Hz), 4.92 (1H, m), 6.37 (1H, d, J=9.4 Hz), 7.22-7.68 (8H, m)

MS(ESI^+) : 350$[M+H]^+$

IR(KBr) : 3364, 2214, 1660, 1572, 1200 cm^{-1}

mp : 207.0°C (IPA-H_2O)

Example 36

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(2-methoxyphenyl)-2-pyrazinecarbonitrile

^{1}H-NMR(DMSO-d_6 δ) : 0.97 (6H, brs), 3.46 (3H, s), 4.86 (1H, m), 6.34 (1H, d, J=9.4 Hz), 6.99 (1H, d, 8.2 Hz), 7.10 (1H, t, 7.6 Hz), 7.18 (1H, d, 2.5 Hz), 7.37-7.50 (5H, m)

MS(ESI^+) : 362$[M+H]^+$, 384$[M+Na]^+$

IR(KBr) : 3266, 2214, 1600, 1448, 1255 cm^{-1}

mp : 222.6°C (IPA-H_2O)

Example 37

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(3-methoxyphenyl)-2-pyrazinecarbonitrile

^{1}H-NMR(DMSO-d_6 δ) : 0.98 (6H, d, J=6.8 Hz), 3.69 (3H, s), 4.91 (1H, m), 6.35 (1H, d, J=9.4 Hz), 6.95-6.97 (1H, m), 7.00 (2H, s), 7.30-7.47 (5H, m)

MS(ESI$^+$) : 362[M+H]$^+$, 384[M+Na]$^+$

IR(KBr) : 3360, 2215, 1655, 1570, 1205 cm^{-1}

mp : 192.3°C (IPA-H_2O)

Example 38

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(4-methoxyphenyl)-2-pyrazinecarbonitrile

^{1}H-NMR(DMSO-d_6 δ) : 1.02 (6H, d, J=6.8 Hz), 3.76 (3H, s), 4.93 (1H, m), 6.35 (1H, d, J=9.4 Hz), 6.98 (2H, d, 7.2Hz), 7.38-7.43 (6H, m)

MS(ESI$^+$) : 362[M+H]$^+$, 384[M+Na]$^+$

IR(KBr) : 3357, 2218, 1650, 1570, 1200 cm^{-1}

mp : 243.9°C (IPA-H_2O)

Example 39

3-Amino-5-(3,4-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarbonitrile

^{1}H-NMR(DMSO-d_6 δ) : 1.02 (6H, d, J=6.8 Hz), 4.95 (1H, m), 6.38 (1H, d, J=9.0 Hz), 7.26 (1H, m), 7.38-7.58 (6H, m),

MS(ESI$^+$) : 368$[M+H]^+$, 390$[M+Na]^+$

IR(KBr) : 3166, 2210, 1658, 1461, 1201 cm^{-1}

mp : 180°C (IPA-H_2O)

Example 40

3-Amino-5-(4-fluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide (30 g) was suspended in dioxane (60 ml) and 2*N aq.* NaOH (600 ml). The mixture was heated at 90°C with stirring for 4 hours. The above reaction mixture was cooled to 25-30°C. The pH of the suspension was adjusted to 2.5 with 35% HCl (105 ml). The precipitate was collected by filtration and washed with water and dried in vacuo at 50°C for 15 hours to give 3-amino-5-(4-fluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid as yellow powder. (29.6 g)

^{1}H-NMR(DMSO-d_6 δ) : 1.00 (6H, d, J=6.8 Hz), 4.93 (1H, m), 6.37 (1H, d, J=9.4 Hz), 7.22-7.36 (3H, m), 7.48-7.68 (5H, m), 13.00 (1H, s)

IR(KBr) : 3266, 1725, 1662, 1600, 1455 cm^{-1}

mp : 222.2°C (IPA-H_2O)

Example 41

3-Amino-5-(4-fluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid (25 g) was suspended in 1,2-dichlorobenzene (125 ml). The suspension was heated at 165-170°C with stirring for 4 hours.

The reaction mixture was cooled to 20-25°C. To the cooled mixture was added IPE (250 ml). The suspension was stirred at 25-30°C for 3 hours. The precipitate was collected by filtration and dried in vacuo. The above dried precipitate was purified by chromatography on silica gel (500 g) eluting with $CHCl_3$: MeOH (9 : 1, 2 l). Evaporation of solvent in vacuo gave yellowish crystal residue, which was recrystallized from 70% EtOH (322 ml) to give 5-[5-amino-3-(4-fluorophenyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone as yellowish crystal (19.4 g).

^{1}H-NMR(DMSO-d_6 δ) : 1.00 (6H, d, J=6.8 Hz), 4.93 (1H, m), 6.33 (1H, d, J=9.2 Hz), 6.63 (2H, s), 7.17-7.26 (3H, m), 7.38-7.46 (3H, m), 7.93 (1H, s)

MS(ESI$^+$) : 325[M+H]$^+$, 347[M+Na]$^+$

IR(KBr) : 3166, 1666, 1604, 1533, 1467, 1222 cm^{-1}

mp : 257.7°C (IPA-H_2O)

Example 42

A mixture of 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylic acid (70 mg), methylamine hydrochloride (14.8 mg), 1-ethyl-3-[3'-(dimethylamino)propyl]-carbodiimide (34.1 mg), and 1-hydroxy-benzotriazole (29.7 mg) in CH_2Cl_2 (0.7 ml) was stirred at 25°C for 4 hours. Water and EtOAc were poured into the mixture. The organic layer was separated, washed with water, *sat. aq.* $NaHCO_3$, and brine, and dried

over $MgSO_4$. The solvent was removed under reduced pressure. The residue was purified by silica-gel column chromatography (*n*-hexane - EtOAc then CH_2Cl_2 - MeOH) and then crystallized from MeOH-IPE to give 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-N-methyl-5-phenyl-2-pyrazinecarboxamide (40 mg).

^{1}H-NMR(DMSO-d_6 δ) : 0.93 (6H, d, J=6.8 Hz), 2.84 (3H, d, J=4.8 Hz), 4.89 (1H, qq, J=6.8, 6.8 Hz), 6.38 (1H, d, J=9.4 Hz), 7.26 (1H, d, J=2.5 Hz), 7.42 (5H, m), 7.62 (2H, brs), 7.79 (1H, dd, J=2.5, 9.4 Hz), 8.69 (1H, m)

MS(ESI$^+$) : 364[M+H]$^+$

The following 4 compounds were obtained in a similar manner to that of Example 42.

Example 43

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-N,N-dimethyl-5-phenyl-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 0.93 (6H, d, J=6.7 Hz), 3.04 (3H, s), 3.10 (3H, s), 4.89 (1H, qq, J=6.7, 6.7 Hz), 6.36 (1H, d, J=9.4 Hz), 6.73 (2H, brs), 7.21 (1H, d, J=2.5 Hz), 7.3-7.6 (6H, m)

MS(ESI$^-$) : 376[M-H]$^-$

Example 44

5-[5-Amino-6-(4-morpholinylcarbonyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 0.95 (6H, d, J=6.8 Hz), 3.63 (4H, brs), 3.70 (4H, brs), 4.86 (1H, qq, J=6.8, 6.8 Hz), 6.36 (1H, d, J=9.4 Hz), 6.78 (2H, brs), 7.24 (1H, d, J=2.4 Hz), 7.3-7.5 (6H, m)

MS(ESI$^+$) : 420[M+H]$^+$

Example 45

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-N-(2-pyridylmethyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 0.94 (6H, d, J=6.8 Hz), 4.64 (2H, d, J=6.0 Hz), 4.87 (1H, qq, J=6.8, 6.8 Hz), 6.39 (1H, d, J=9.4 Hz), 7.1-7.9 (12H, m), 8.52 (1H, distorted d, J=4.1 Hz), 9.37 (1H, t, J=6.0 Hz).

MS(ESI$^+$) : 441[M+H]$^+$

Example 46

3-Amino-N-(cyanomethyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide.

^{1}H-NMR(DMSO-d_6 δ) : 0.92 (6H, d, J=6.8 Hz), 4.34 (2H, d, J=5.9 Hz), 4.88 (1H, qq, J=6.8, 6.8 Hz), 6.41 (1H, d, J=9.4 Hz), 7.24 (1H, d, J=2.4 Hz), 7.3-7.5 (5H, m), 7.61 (2H, brs), 7.83 (1H, dd, J=2.4, 9.4 Hz), 9.27 (1H, brt, J=5.9 Hz)

MS(ESI$^+$) : 389[M+H]$^+$, 411[M+Na]$^+$

Example 47

To a mixture of 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylic acid (70 mg) and NEt_3 (40.4 mg) in THF (0.7 ml), was added

isobutyl chloroformate (32.7 mg) under ice-bath cooling. After 1.5 hours stirring at the same temperature, the mixture was poured into a mixture of sodium borohydride (30.2 mg) in a mixture of THF (0.7 ml) and water (1.4 ml) under ice-bath cooling. After 2.5 hours stirring at the same temperature, the mixture was diluted with water and EtOAc, and then the organic layer was separated, washed with water and brine, and dried over $MgSO_4$. The solvent was removed under reduced pressure. The residue was purified by silica-gel column chromatography (CH_2Cl_2 : MeOH=25 : 1 - 10 : 1). A desired fraction was triturated with IPE to give 5-[5-amino-6-(hydroxymethyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone (24 mg).

^{1}H-NMR(DMSO-d_6 δ) : 0.95 (6H, d, J=6.8 Hz), 4.59 (2H, d, J=5.6 Hz), 4.90 (1H, qq, J=6.8, 6.8 Hz), 5.34 (1H, t, J=5.6 Hz), 6.3-6.4 (3H, m), 7.20 (1H, d, J=2.4 Hz), 7.2-7.5 (5H, m), 7.50 (1H, dd, J=2.4, 9.4 Hz)

MS(ESI$^+$) : 337[M+H]$^+$, 359[M+Na]$^+$

The following 3 compounds were obtained in a similar manner to that of Example 42.

Example 48

5-[5-Amino-6-(1-azetidinylcarbonyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1H)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 0.92 (6H, d, J=6.8 Hz), 2.25 (2H, m), 4.09 (2H, t, J=7.6 Hz), 4.70 (2H, t, J=7.6 Hz), 4.91 (1H,

qq, J=6.8, 6.8 Hz), 6.36 (1H, d, J=9.4 Hz), 7.29 (1H, d, J=2.4 Hz), 7.3-7.6 (6H, m), 7.62 (2H, brs)

MS(ESI$^+$) : 390[M+H]$^+$

Example 49

3-Amino-N-(2-hydroxyethyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 0.93 (6H, d, J=6.8 Hz), 3.4-3.5 (2H, m), 3.5-3.6 (2H, m), 4.7-5.0 (2H, m), 6.39 (1H, d, J=9.4 Hz), 7.26 (1H, 2.4 Hz), 7.3-7.5 (5H, m), 7.63 (2H, brs), 7.75 (1H, dd, J=2.4, 9.4 Hz), 8.63 (1H, t, J=5.8 Hz)

MS(ESI$^+$) : 394[M+H]$^+$, 416[M+Na]$^+$

Example 50

3-Amino-N-cyclopropyl-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 0.6-0.8 (4H, m), 0.93 (6H, d, J=6.8 Hz), 2.84 (1H, m), 4.89 (1H, qq, J=6.8, 6.8 Hz), 6.37 (1H, d, J=9.4 Hz), 7.29 (1H, d, J=2.4 Hz), 7.3-7.5 (5H, m), 7.61 (2H, brs), 7.75 (1H, dd, J=2.4, 9.4 Hz), 8.57 (1H, t, J=4.2 Hz)

MS(ESI$^+$) : 390[M+H]$^+$, 412[M+Na]$^+$

Example 51

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylic acid

The title compound was obtained in a similar manner to that of Example 40.

^{1}H-NMR(DMSO-d_6 δ) : 0.95 (6H, d, J=6.8 Hz), 4.90 (1H, qq, J=6.8, 6.8 Hz), 6.37 (1H, d, J=9.4 Hz), 7.31 (1H, d, J=2.4 Hz), 7.2-7.6 (7H, m), 7.59 (1H, dd, J=2.4, 9.4 Hz), 13.0 (1H, brs)

MS(ESI$^-$) : 349[M-H]$^-$

Example 52

5-(5-Amino-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone

The title compound was obtained in a similar manner to that of Example 41.

^{1}H-NMR(DMSO-d_6 δ) : 0.95 (6H, d, J=6.8 Hz), 4.90 (1H, qq, J=6.8, 6.8 Hz), 6.32 (1H, d, J=9.4 Hz), 6.60 (2H, brs), 7.21 (1H, d, J=2.4 Hz), 7.2-7.5 (6H, m), 7.93 (1H, s)

MS(ESI$^+$) : 307[M+H]$^+$, 329[M+Na]$^+$

Example 53

A mixture of 5-(5-amino-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (100 mg) and N-bromosuccinimide (87.1 mg) in DMF was heated at 50°C with stirring for 20 minutes. *Sat. aq.* $NaHCO_3$ and EtOAc were poured into the mixture. The organic layer was separated, washed with water and brine, and dried over $MgSO_4$. The solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (*n*-hexane : EtOAc=10 : 1 - 2 : 1). A desired product was recrystallized with IPE and dried in vacuo to give

5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-3-bromo-1-isopropyl-2(1*H*)-pyridone (57 mg).

^{1}H-NMR(DMSO-d_6 δ) : 0.94 (6H, d, J=6.8 Hz), 4.89 (1H, qq, J=6.8, 6.8 Hz), 6.97 (2H, brs), 7.24 (1H, d, J=2.4 Hz), 7.2-7.6 (5H, m), 7.92 (1H, d, J=2.4 Hz)

MS(ESI$^+$) : 463[M+H]$^+$

Example 54

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-N-methoxy-N-methyl-5-phenyl-2-pyrazinecarboxamide

The title compound was obtained in a similar manner to that of Example 42.

^{1}H-NMR(DMSO-d_6 δ) : 0.94 (6H, d, J=6.8 Hz), 3.36 (3H, s), 3.75 (3H, s), 4.89 (1H, qq, J=6.8, 6.8 Hz), 6.36 (1H, d, J=9.3 Hz), 6.79 (2H, brs), 7.24 (1H, d, J=2.4 Hz), 7.3-7.6 (6H, m)

MS(ESI$^+$) : 394[M+H]$^+$

Example 55

5-(5-Amino-6-chloro-3-phenyl-2-pyrazinyl)-3-chloro-1-isopropyl-2(1H)-pyridone

The title compound was obtained in a similar manner to that of Example 53.

^{1}H-NMR(DMSO-d_6 δ) : 0.95 (6H, d, J=6.8 Hz), 4.90 (1H, qq, J=6.8, 6.8 Hz), 7.05 (2H, brs), 7.22 (1H, d, J=2.4 Hz), 7.2-7.6 (5H, m), 7.74 (1H, d, J=2.4 Hz)

MS(ESI$^+$) : 375[M+H]$^+$, 397[M+Na]$^+$

Example 56

5-{5-Amino-6-[(3-methoxy-1-azetidinyl)carbonyl]-3-phenyl-2-pyrazinyl}-1-isopropyl-2(1H)-pyridone

The title compound was obtained in a similar manner to that of Example 1.

^{1}H-NMR(DMSO-d_6 δ) : 1.00 (6H, d, J=6.8 Hz), 3.24 (3H, s), 3.8-4.0 (1H, m), 4.2-4.5 (2H, m), 4.4-4.6 (1H, m), 4.8-5.1 (2H, m), 6.35 (1H, J=9.2 Hz), 7.3-7.5 (7H, m), 7.62 (2H, brs)

MS(ESI$^+$) : 420[M+H]$^+$

Example 57

Under ice-bath cooling, to a suspension of 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-N-methoxy-N-methyl-5-phenyl-2-pyrazinecarboxamide (200 mg) in THF (4.0 ml) was added 3.0*M* solution of methylmagnesium chloride in THF (0.85 ml) dropwise. The mixture was stirred at the same temperature for 5 hours. The mixture was poured into *sat. aq* ammonium chloride (20 ml) and an organic layer was extracted with EtOAc (50 ml), washed with water and brine, and dried over $MgSO_4$. The solvent was removed under reduced pressure. The residue was purified by silica-gel column chromatography (CH_2Cl_2 : MeOH=50 : 1 - 15 : 1). The desired fraction was recrystallized from MeOH and dried in vacuo to give 5-(6-acetyl-5-amino- 3-phenyl-2-pyrazinyl)-1-isopropyl-

2(1H)-pyridone (111 mg).

^{1}H-NMR(DMSO-d_6 δ) : 0.95 (6H, d, J=6.8 Hz), 2.66 (3H, s), 4.91 (1H, qq, J=6.8, 6.8 Hz), 6.41 (1H, d, J=9.4 Hz), 7.30 (1H, d, J=2.4 Hz), 7.3-7.6 (5H, m), 7.61 (1H, dd, J=2.4, 9.4 Hz), 7.81 (2H, brs)

MS(ESI$^+$) : 249$[M+H]^+$, 371$[M+Na]^+$

Example 58

3-Amino-N-[2-(dimethylamino)ethyl]-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxamide

The title compound was obtained in a similar manner to that of Example 42.

^{1}H-NMR(DMSO-d_6 δ) : 0.97 (6H, d, J=6.8 Hz), 2.20 (6H, s), 2.42 (2H, t, J=6.6 Hz), 3.3-3.5 (2H, m), 4.91 (1H, qq, J=6.8, 6.8 Hz), 6.37 (1H, d, J=9.4 Hz), 7.31 (1H, d, J=2.4 Hz), 7.3-7.5 (5H, m), 7.66 (1H, dd, J=2.4, 9.4 Hz), 8.62 (1H, t, J=5.7 Hz)

MS(ESI$^+$) : 421$[M+H]^+$

Example 59

3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarbonitrile

The title compound was obtained in a similar manner to that of Example 1.

^{1}H-NMR(DMSO-d_6 δ) : 3.40 (3H, s), 6.17 (1H, d, J=9.4 Hz), 6.97 (1H, dd, J=2.6, 9.4 Hz), 7.40-7.49 (7H, m), 7.81 (1H,

d, J=2.6 Hz)

MS(ESI$^+$) : 304[M+H]$^+$, 326[M+Na]$^+$

IR(KBr) : 3386, 2221, 1670, 1590, 1542, 1205 cm^{-1}

Example 60

A mixture of 3-amino-5-chloro-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide (500 mg), (4-methoxyphenyl)boronic acid (740 mg), and $Pd(PPh_3)_4$ (56.3 mg) in 2*M* *aq.* Na_2CO_3 (3.25 ml) and dioxane (20 ml) was refluxed for 3 hours. Water (40 ml) and of EtOAc (30 ml) were poured into the reaction mixture and the aqueous solution was extracted with EtOAc. The organic layer was washed with water and brine, and dried over $MgSO_4$. After filtration, the solvent was removed under reduced pressure. The residual solid was placed on a column of silica-gel and eluted with $CHCl_3$: MeOH (25 : 1). The eluent was evaporated and the residue was suspended with IPE and filtrated to give 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(4-methoxyphenyl)-2-pyrazinecarboxamide (512 mg) as a yellow powder.

^{1}H-NMR(DMSO-d_6 δ) : 1.05 (6H, d, J=7.0 Hz), 4.94 (1H, sept, J=7.0 Hz), 6.32 (1H, d, J=9.5 Hz), 6.98 (2H, d, J=9.0 Hz), 7.39-7.64 (7H, m), 8.15(1H, brs)

MS(ESI$^+$) : 380[M+H]$^+$, 421[M+H+MeCN]$^+$

The following 18 compounds were obtained in a similar manner to that of Example 60.

Example 61

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(2-methoxyphenyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 0.89 (6H, brs), 3.48 (3H, s), 4.88 (1H, sept, J=6.8 Hz), 6.32 (1H, d, J=9.5 Hz), 7.00-7.13 (2H, m), 7.22 (1H, d, J=2.5 Hz), 7.37-7.79 (6H, m), 8.16 (1H, brs)

Example 62

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(3-methoxyphenyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 1.00 (6H, d, J=7.0 Hz), 3.71 (3H, s), 4.92 (1H, sept, J=7.0 Hz), 6.33 (1H, d, J=9.5 Hz), 6.94-7.02 (3H, m), 7.30-7.39 (2H, m), 7.65-7.71 (4H, m), 8.20 (1H, brs)

Example 63

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(2-methylphenyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 0.88 (6H, d, J=7.0 Hz), 1.99 (3H, s), 4.85 (1H, sept, J=7.0 Hz), 6.33 (1H, d, J=9.5 Hz), 7.11 (1H, d, J=2.5 Hz), 7.32 (4H, brs), 7.70 (3H, brs), 7.89 (1H, dd, J=2.5, 9.5 Hz), 8.23 (1H, brs)

MS(ESI$^+$) : 364[M+H]$^+$, 405[M+H+MeCN]$^+$

Example 64

3-Amino-5-(2,3-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 0.97 (6H, d, J=7.0 Hz), 4.92 (1H, sept,

J=7.0 Hz), 6.37 (1H, d, J=9.0 Hz), 7.34-7.79 (8H, m), 8.26 (1H, brs)

MS(ESI$^+$) : 386[M+H]$^+$, 427[M+H+MeCN]$^+$

Example 65

3-Amino-5-(2,4-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 0.99 (6H, d, J=6.8 Hz), 4.93 (1H, sept, J=6.8 Hz), 6.36 (1H, d, J=9.0 Hz), 7.24-7.35 (3H, m), 7.65-7.77 (5H, m), 8.23 (1H, brs)

MS(ESI$^+$) : 386[M+H]$^+$, 427[M+H+MeCN]$^+$

Example 66

3-Amino-5-(2,5-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 0.99 (6H, d, J=7.0 Hz), 4.92 (1H, sept, J=7.0 Hz), 6.37 (1H, d, J=9.5 Hz), 7.24-7.40 (3H, m), 7.48-7.79 (5H, m), 8.25 (1H, brs)

MS(ESI$^+$) : 386[M+H]$^+$, 427[M+H+MeCN]$^+$

Example 67

3-Amino-5-(2-furyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 1.25 (6H, d, J=6.8 Hz), 5.07 (1H, sept, J=6.8 Hz), 6.39 (1H, d, J=9.0 Hz), 6.61 (1H, dd, J=1.1, 3.5 Hz), 6.79 (1H, d, J=3.5 Hz), 7.55 (1H, dd, J=2.5, 9.5 Hz), 7.66 (3H, brs), 7.79 (2H, brs), 8.09 (1H, brs)

MS(ESI$^+$) : 340[M+H]$^+$, 381[M+H+MeCN]$^+$

Example 68

3-Amino-5-(3-furyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 1.25 (6H, d, J=6.8 Hz), 5.07 (1H, sept, J=6.8 Hz), 6.39 (1H, d, J=9.0 Hz), 6.62 (1H, dd, J=2.0, 3.5 Hz), 6.79 (1H, d, J=3.5 Hz), 7.55(1H, dd, J=2.5, 9.5 Hz), 7.66 (3H, brs), 7.99 (2H, s), 8.09 (1H, brs)

MS(ESI$^+$) : 340[M+H]$^+$, 381[M+H+MeCN]$^+$

Example 69

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(2-thienyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 1.23 (6H, d, J=6.8 Hz), 5.07 (1H, sept, J=6.8 Hz), 6.42 (1H, d, J=9.5 Hz), 7.04-7.06 (1H, m), 7.16-7.17 (1H, m), 7.49 (1H, d, J=2.5 Hz), 7.54 (1H, d, J=2.5 Hz), 7.65 (2H, brs), 7.69 (1H, d, J=5.5 Hz), 7.87 (1H, d, J=2.5 Hz), 8.06 (1H, brs)

MS(ESI$^+$) : 356[M+H]$^+$, 397[M+H+MeCN]$^+$

Example 70

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(3-thienyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 1.12 (6H, d, J=7.0 Hz), 4.98 (1H, sept, J=7.0 Hz), 6.36 (1H, d, J=9.0 Hz), 7.12 (1H, dd, J=1.3, 5.0 Hz), 7.54-7.71 (7H, m), 8.14 (1H, brs)

MS(ESI$^+$) : 356[M+H]$^+$, 397[M+H+MeCN]$^+$

Example 71

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(5-methyl-2-thienyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 1.26 (6H, d, J=6.5 Hz), 2.44 (3H, s), 5.08 (1H, sept, J=6.8 Hz), 6.41 (1H, d, J=9.5 Hz), 6.76 (1H, d, J=2.5 Hz), 6.98 (1H, d, J=3.5 Hz), 7.47 (1H, d, J=2.5 Hz), 7.52 (1H, d, J=2.5 Hz), 7.61 (2H, brs), 7.89 (1H, d, J=2.5 Hz), 8.01 (1H, brs)

MS(ESI$^+$) : 370[M+H]$^+$, 411[M+H+MeCN]$^+$

Example 72

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(1*H*-pyrazol-4-yl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 1.23 (6H, d, J=7.0 Hz), 5.06 (1H, sept, J=7.0 Hz), 6.40 (1H, d, J=9.5 Hz), 7.50 (1H, dd, J=2.5, 9.5 Hz), 7.57 (5H, brs), 7.80 (1H, d, J=2.5 Hz), 8.01 (1H, brs), 13.06 (1H, brs)

MS(ESI$^+$) : 362[M+Na]$^+$, 701[2M+Na]$^+$

Example 73

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-[(E)-2-phenylvinyl]-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 1.32 (6H, d, J=6.5 Hz), 5.12 (1H, sept, J=6.5 Hz), 6.50 (1H, d, J=9.5 Hz), 7.20-7.43 (5H, m), 7.59-7.83 (6H, m), 7.90 (1H, d, J=2.5 Hz), 8.10 (1H, brs)

MS(ESI$^+$) : 398[M+Na]$^+$, 773[2M+Na]$^+$

Example 74

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(3-pyridyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 0.98 (6H, d, J=7.0 Hz), 4.93 (1H, sept, J=7.0 Hz), 6.36 (1H, d, J=9.5 Hz), 7.37-7.46 (3H, m), 7.66-7.75 (4H, m), 8.26 (1H, brs), 8.61-8.64 (2H, m)

MS(ESI$^+$) : 351[M+H]$^+$, 392[M+H+MeCN]$^+$

Example 75

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(4-pyridyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 1.00 (6H, d, J=7.0 Hz), 4.93 (1H, sept, J=7.0 Hz), 6.35 (1H, d, J=9.5 Hz), 7.42-7.89 (7H, m), 8.23 (1H, brs), 8.57 (1H, dd, J=2.0, 5.0 Hz), 8.64 (1H, d, J=2.0 Hz)

MS(ESI$^+$) : 351[M+H]$^+$, 392[M+H+MeCN]$^+$

Example 76

3-Amino-5-(4-fluorophenyl)-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 3.46 (3H, s), 6.17 (1H, d, J=9.5 Hz), 7.00 (1H, dd, J=2.5, 9.5 Hz), 7.25 (2H, t, J=9 Hz), 7.51-7.73 (5H, m), 8.15 (1H, d, J=2.5 Hz), 8.27 (1H, brs)

MS(ESI$^+$) : 362[M+Na]$^+$, 701[2M+Na]$^+$

Example 77

3-Amino-5-(2-furyl)-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 3.50 (3H, s), 6.33 (1H, d, J=9.0 Hz), 6.63 (1H, dd, J=1.8, 3.5 Hz), 6.83 (1H, d, J=3.5 Hz), 7.28

(1H, dd, J=2.5, 9.5 Hz), 7.69-7.79 (4H, m), 8.10 (1H, d, J=2.5 Hz), 8.16 (1H, brs)

MS(ESI$^+$) : 334[M+Na]$^+$

Example 78

3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(2-thienyl)-2-pyrazinecarboxamide

^{1}H-NMR(DMSO-d_6 δ) : 3.50 (3H, s), 6.35 (1H, d, J=9.5 Hz), 7.04-7.09 (1H, m), 7.19-7.21 (1H, m), 7.35 (1H, dd, J=2.5, 9.5 Hz), 7.66 (1H, brs), 7.70-7.72 (3H, m), 8.12-8.13 (2H, m)

MS(ESI$^+$) : 350[M+Na]$^+$

Example 79

A mixture of 3-amino-5-chloro-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide (200 mg), ethynylbenzen (331 mg), NEt_3 (658 mg), triphenylphosphine (17 mg), CuI (6.2 mg), and $PdCl_2(PPh_3)_2$ (23 mg) in DMF (2 ml) was heated at 80°C for 18 hours. Water (20 ml) and EtOAc (20 ml) were poured into the reaction mixture and the aqueous solution was extracted with EtOAc. The organic layer was washed with water and brine, and dried over $MgSO_4$. After filtration, the solvent was removed under reduced pressure. The residual solid was placed on a column of silica-gel and eluted with $CHCl_3$ - MeOH (97 : 3). The eluent was evaporated and the residue was suspended with IPE and filtrated to give 3-amino-6-(1-isopropyl-6-oxo-

1,6-dihydro-3-pyridyl)-5-(phenylethynyl)-2-pyrazinecarboxamide (218 mg) as a yellow powder.

MS(ESI$^+$) : 396[M+Na]$^+$, 769[2M+Na]$^+$

Example 80

A toluene solution of 3-amino-5-chloro-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide (200 mg), 2-(tributylstannyl)pyridine (311 mg), and $Pd(PPh_3)_4$ (22.5 mg) was refluxed for 5 hours. Water (20 ml) and EtOAc (15 ml) were poured into the reaction mixture and the aqueous solution was extracted with EtOAc. The organic layer was washed with water and brine, and dried over $MgSO_4$. After filtration, the solvent was removed under reduced pressure. The residual solid was placed on a column of silica-gel and eluted with $CHCl_3$ - MeOH (97 : 3). The eluent was evaporated and the residue was suspended with IPE and filtrated to give 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(2-pyridyl)-2-pyrazinecarboxamide (64 mg) as a yellow powder.

^{1}H-NMR(DMSO-d_6 δ) : 1.01 (6H, d, J=6.5 Hz), 4.93 (1H, sept, J=6.5 Hz), 6.30 (1H, d, J=9.5 Hz), 7.35-7.46 (2H, m), 7.59-7.75 (5H, m), 7.96 (1H, dt, J=1.7, 7.8 Hz), 8.24 (1H, brs), 8.55 (1H, d, J=4.5 Hz)

MS(ESI$^+$) : 351[M+H]$^+$

Example 81

To a suspention of 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(4-methoxyphenyl)-2-pyrazinecarboxamide (210 mg) in dioxane (2 ml) was added an *aq.* NaOH (*2M*, 4 ml) and this solution was heated at 100°C for 4 hours. This reaction mixture was cooled to room temperature and the pH of this solution was adjusted to 2.5 with *2N aq.* HCl. The precipitate was collected by filtration and washed with water to give 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(4-methoxyphenyl)-2-pyrazinecarboxylic acid (203 mg) as a yellow powder.

^{1}H-NMR(DMSO-d_6 δ) : 1.03 (1H, d, J=7 Hz), 3.77 (3H, s), 4.94 (1H, sept, J=7.0 Hz), 6.36 (1H, d, J=9.5 Hz), 6.98 (2H, d, J=9.0 Hz), 7.41-7.56 (6H, m), 12.91 (1H, brs)

MS(ESI$^+$) : 381[M+H]$^+$, 422[M+H+MeCN]$^+$

The following 24 compounds were obtained in a similar manner to that of Example 81.

Example 82

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(2-methoxyphenyl)-2-pyrazinecarboxylic acid

^{1}H-NMR(DMSO-d_6 δ) : 0.91 (6H, brs), 3.48 (3H, s), 4.87 (1H, sept, J=6.8 Hz), 6.35 (1H, d, J=9.5 Hz), 7.01 (1H, d, J=8 Hz), 7.10 (1H, t, J=7.5 Hz), 7.19 (1H, d, J=2.5 Hz), 7.38-7.49 (4H, m), 7.62 (1H, dd, J=2.5, 9.0 Hz), 12.93 (1H, brs)

MS(ESI$^+$) : 381[M+H]$^+$, 422[M+H+MeCN]$^+$

Example 83

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(3-methoxyphenyl)-2-pyrazinecarboxylic acid

^{1}H-NMR(DMSO-d_6 δ) : 0.99 (6H, d, J=7 Hz), 3.70 (3H, s), 4.92 (1H, sept, J=7.0 Hz), 6.37 (1H, d, J=9.5 Hz), 6.95-7.04 (3H, m), 7.30-7.38 (2H, m), 7.50 (2H, brs), 7.58 (1H, dd, J=2.5, 9.0 Hz), 13 (1H, brs)

MS(ESI$^+$) : 381[M+H]$^+$, 422[M+H+MeCN]$^+$

Example 84

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(2-methylphenyl)-2-pyrazinecarboxylic acid

^{1}H-NMR(DMSO-d_6 δ) : 0.88 (6H, d, J=7.0 Hz), 1.99 (3H, s), 4.85 (1H, t, J=7.0 Hz), 6.37 (1H, d, J=9.5 Hz), 7.09 (1H, d, J=2.5 Hz), 7.26 - 7.40 (4H, m), 7.49 (2H, brs), 7.73 (1H, dd, J=2.5, 9.5 Hz), 13.05 (1H, brs)

Example 85

3-Amino-5-(2,3-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

^{1}H-NMR(DMSO-d_6 δ) : 0.95 (6H, d, J=3.5 Hz), 4.92 (1H, sept, J=3.5 Hz), 6.40 (1H, d, J=4.7 Hz), 7.30 (1H, d, J=1.1 Hz), 7.34-7.63 (6H, m), 13.20 (1H, brs)

MS(ESI$^+$) : 387[M+H]$^+$, 428[M+H+MeCN]$^+$

Example 86

3-Amino-5-(2,4-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

^{1}H-NMR(DMSO-d_6 δ) : 0.97 (6H, d, J=3.4 Hz), 4.92 (1H, sept, J=3.4 Hz), 6.39 (1H, d, J=4.8 Hz), 7.26-7.33 (3H, m), 7.56 (2H, brs), 7.61 (1H, dd, J=1.3, 4.8 Hz), 7.68-7.74 (1H, m), 13.15 (1H, brs)

MS(ESI$^+$) : 387[M+H]$^+$, 428[M+H+MeCN]$^+$

Example 87

3-Amino-5-(2,5-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

^{1}H-NMR(DMSO-d_6 δ) : 0.97 (6H, d, J=3.5 Hz), 4.92 (1H, sept, J=3.5 Hz), 6.4 (1H, d, J=4.8 Hz), 7.25-7.38 (3H, m), 7.51-7.55 (1H, m), 7.58 (2H, brs), 7.62 (1H, dd, J=1.3, 4.8 Hz), 13.19 (1H, brs)

MS(ESI$^+$) : 387[M+H]$^+$, 428[M+H+MeCN]$^+$

Example 88

3-Amino-5-(2-furyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

^{1}H-NMR(DMSO-d_6 δ) : 1.24 (6H, d, J=6.5 Hz), 5.09 (1H, sept, J=6.5 Hz), 6.43 (1H, d, J=9 Hz), 6.62 (1H, dd, J=2, 3.5 Hz), 6.77 (1H, d, J=3 Hz), 7.45-7.51 (3H, m), 7.75-7.82 (2H, m)

Example 89

3-Amino-5-(3-furyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

^{1}H-NMR(DMSO-d_6 δ) : 1.21 (6H, d, J=3.5 Hz), 5.06 (1H, sept, J=3.5 Hz), 6.43 (1H, d, J=4.8 Hz), 6.54 (1H, d, J=0.9 Hz), 7.44 (2H, brs), 7.48 (1H, dd, J=1.3, 4.8 Hz), 7.72-7.77 (3H,

m), 12.95 (1H, brs)

MS(ESI$^+$) : 341[M+H]$^+$, 382[M+H+MeCN]$^+$

Example 90

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(2-thienyl)-2-pyrazinecarboxylic acid

^{1}H-NMR(DMSO-d_6 δ) : 1.22 (6H, d, J=7.0 Hz), 5.08 (1H, sept, J=7.0 Hz), 6.46 (1H, d, J=9.0 Hz), 7.05-7.09 (1H, m), 7.2 (1H, dd, J=1.0, 4.0 Hz), 7.42-7.48 (3H, m), 7.73 (1H, dd, J=1.0, 5.0 Hz), 7.83 (1H, d, J=2.5 Hz), 13.00 (1H, brs)

MS(ESI$^+$) : 357[M+H]$^+$, 398[M+H+MeCN]$^+$

Example 91

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(3-thienyl)-2-pyrazinecarboxylic acid

^{1}H-NMR(DMSO-d_6 δ) : 1.10 (6H, d, J=6.5 Hz), 4.98 (1H, sept, J=6.5 Hz), 6.37-6.43 (1H, m), 7.13 (1H, dd, J=1.5, 5.0 Hz), 7.46-7.60 (5H, m), 7.72 (1H, dd, J=1.3, 3 Hz)

MS(ESI$^+$) : 357[M+H]$^+$, 398[M+H+MeCN]$^+$

Example 92

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(5-methyl-2-thienyl)-2-pyrazinecarboxylic acid

^{1}H-NMR(DMSO-d_6 δ) : 1.25 (6H, d, J=7.0 Hz), 5.09 (1H, sept, J=7.0 Hz), 2.44 (3H, s), 6.45 (1H, d, J=9.5 Hz), 6.77-6.78 (1H, m), 7.01 (1H, d, J=3.5 Hz), 7.40-7.46 (3H, m), 7.85 (1H, d, J=2.5 Hz), 12.98 (1H, brs)

MS(ESI$^+$) : 371[M+H]$^+$, 412[M+H+MeCN]$^+$

Example 93

3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(1*H*-pyrazol-4-yl)-2-pyrazinecarboxylic acid

^{1}H-NMR(DMSO-d_6 δ) : 1.23 (1H, d, J=7.0 Hz), 5.07 (1H, sept, J=7.0 Hz), 6.44 (1H, d, J=9.0 Hz), 7.37 (2H, brs), 7.43 (1H, dd, J=2.5, 9.0 Hz), 7.66 (2H, s), 7.77 (1H, d, J=2.5 Hz), 12.99 (1H, brs)

MS(ESI$^-$) : 339[M-H]$^-$

Example 94

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-[(E)-2-phenylvinyl]-2-pyrazinecarboxylic acid

MS(ESI$^-$) : 375[M-H]$^-$

Example 95

3-Amino-5-(4-fluorophenyl)-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

^{1}H-NMR(DMSO-d_6 δ) : 3.43 (3H, s), 6.22 (1H, d, J=9.5 Hz), 7.05 (1H, dd, J=2.8, 9.5 Hz), 7.26 (2H, t, J=8.8 Hz), 7.50 (2H, brs), 7.55 (2H, dd, J=5.5, 9.0 Hz), 7.92 (1H, d, J=2.5 Hz)

Example 96

3-Amino-5-(2-furyl)-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

MS(ESI$^-$) : 311[M-H]$^-$

Example 97

3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-

5-(2-thienyl)-2-pyrazinecarboxylic acid

^{1}H-NMR(DMSO-d_6 δ) : 3.49 (3H, s), 6.40 (1H, d, J=9.5 Hz), 7.08 (1H, dd, J=4.0, 5.0 Hz), 7.22 (1H, dd, J=1.0, 4.0 Hz), 7.36 (1H, dd, J=2.8, 9.5 Hz), 7.48 (2H, brs), 7.74 (1H, dd, J=1.0, 5.0 Hz), 7.97 (1H, d, J=2.5 Hz)

Example 98

3-Amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(phenylethynyl)-2-pyrazinecarboxylic acid

MS(ESI$^-$) : 373[M-H]$^-$

Example 99

3-Amino-5-(2-fluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

^{1}H-NMR(DMSO-d_6 δ) : 0.92 (1H, d, J=7.0 Hz), 4.88 (1H, sept, J=7.0 Hz), 6.38 (1H, d, J=9.5 Hz), 7.18-7.69 (8H, m), 13.12 (1H, brs)

MS(ESI$^+$) : 369[M+H]$^+$, 410[M+H+MeCN]$^+$

Example 100

3-Amino-5-(3-fluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

^{1}H-NMR(DMSO-d_6 δ) : 0.99 (6H, d, J=6.5 Hz), 4.93 (1H, t, J=6.5 Hz), 6.38 (1H, d, J=9.0 Hz), 7.22-7.60 (8H, m), 13.07 (1H, brs)

MS(ESI$^+$) : 369[M+H]$^+$, 410[M+H+MeCN]$^+$

Example 101

3-Amino-5-(3-chlorophenyl)-6-(1-isopropyl-6-oxo-

1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

^{1}H-NMR(DMSO-d_6 δ) : 0.99 (1H, d, J=7.0 Hz), 4.94 (1H, sept, J=7.0 Hz), 6.39 (1H, d, J=9.5 Hz), 7.37-7.62 (8H, m), 13.06 (1H, brs)

MS(ESI$^+$) : 385[M+H]$^+$, 426[M+H+MeCN]$^+$

Example 102

3-Amino-5-(4-chlorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

^{1}H-NMR(DMSO-d_6 δ) : 1.00 (6H, d, J=7.0 Hz), 4.94 (1H, t, J=7.0 Hz), 6.38 (1H, d, J=9.5 Hz), 7.34-7.59 (8H, m), 13.04 (1H, brs)

MS(ESI$^+$) : 385[M+H]$^+$, 426[M+H+MeCN]$^+$

Example 103

3-Amino-5-(3,4-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

^{1}H-NMR(DMSO-d_6 δ) : 1.03 (6H, d, J=7.0 Hz), 4.96 (1H, sept, J=6.8 Hz), 6.39 (1H, d, J=9.0 Hz), 7.30-7.61 (7H, m), 13.06 (1H, brs)

MS(ESI$^+$) : 387[M+H]$^+$, 428[M+H+MeCN]$^+$

Example 104

3-Amino-5-(3,5-difluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxylic acid

^{1}H-NMR(DMSO-d_6 δ) : 1.03 (1H, d, J=6.5 Hz), 4.97 (1H, sept, J=6.5 Hz), 6.40 (1H, d, J=9.5 Hz), 7.16-7.59 (7H, m), 13.16 (1H, brs)

MS(ESI$^+$) : 387[M+H]$^+$, 428[M+H+MeCN]$^+$

Example 105

3-Amino-6-(1-methyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylic acid

^{1}H-NMR(DMSO-d_6 δ) : 3.42 (3H, s), 6.18 (1H, d, J=9.0 Hz), 7.03 (1H, dd, J=2.8, 9.0 Hz), 7.38-7.53 (7H, m), 7.91 (1H, d, J=2.5 Hz)

Example 106

A suspention of 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(4-methoxyphenyl)-2-pyrazinecarboxylic acid in 1,2-dichlorobenzen (3 ml) was heated at 200°C and stirred for 4 hours. This reaction mixture was cooled to room temperature. To this solution was added IPE and stirred at room temperature for 1 hour. The precipitate was collected by filtration and washed with IPE. The residual solid was placed on a column of silica-gel and eluted with $CHCl_3$ - MeOH (20 : 1). The eluent was evaporated and the residue was purified by recrystallization from EtOH - water to give 5-[5-amino-3-(4-methoxyphenyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone (88 mg) as a pale brown crystal.

^{1}H-NMR(DMSO-d_6 δ) : 1.02 (6H, d, J=7.0 Hz), 3.75 (3H, s), 4.94 (1H, sept, J=7.0 Hz), 6.31 (1H, d, J=9.5 Hz), 6.55 (2H, brs), 6.94 (2H, d, J=9.0 Hz), 7.29-7.42 (4H, m), 7.87 (1H, s)

MS(ESI$^+$) : 337[M+H]$^+$, 378[M+H+MeCN]$^+$

The following 24 compounds were obtained in a similar manner to that of Example 106.

Example 107

5-[5-Amino-3-(2-methoxyphenyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 0.91 (6H, brs), 3.48 (3H, s), 4.87 (1H, sept, J=6.8 Hz), 6.31 (1H, d, J=9.0 Hz), 6.51 (2H, brs), 6.97-7.10 (3H, m), 7.33-7.51 (3H, m), 7.90 (1H, s)

MS(ESI$^+$) : 337[M+H]$^+$, 378[M+H+MeCN]$^+$

Example 108

5-[5-Amino-3-(3-methoxyphenyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 0.98 (6H, d, J=7.0 Hz), 3.69 (3H, s), 4.92 (1H, sept, J=7.0 Hz), 6.32 (1H, d, J=9.5 Hz), 6.61 (2H, brs), 6.89-6.95 (3H, m), 7.24-7.33 (3H, m), 7.43 (1H, dd, J=2.5, 9.5 Hz), 7.92 (1H, s)

Example 109

5-[5-Amino-3-(2-methylphenyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 0.88 (6H, d, J=6.5 Hz), 1.97 (3H, s), 4.84 (1H, sept, J=6.5 Hz), 6.32 (1H, d, J=9.0 Hz), 6.58 (2H, brs), 7.02 (1H, d, J=2.5 Hz), 7.27 (4H, brs), 7.56 (1H, dd, J=2.5, 9.0 Hz), 7.95 (1H, s)

Example 110

5-[5-Amino-3-(2,3-difluorophenyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 0.96 (6H, d, J=7 Hz), 4.91 (1H, sept, J=7 Hz), 6.36 (1H, d, J=9.5 Hz), 6.75 (2H, brs), 7.2 (1H, d, J=2.5 Hz), 7.3-7.51 (4H, m), 8.01 (1H, s)

MS(ESI$^+$) : 343[M+H]$^+$, 484[M+H+MeCN]$^+$

Example 111

5-[5-Amino-3-(2,4-difluorophenyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 0.97 (6H, d, J=7.0 Hz), 4.92 (1H, t, J=7.0 Hz), 6.35 (1H, d, J=9.0 Hz), 6.7 (2H, brs), 7.19-7.30 (3H, m), 7.47 (1H, dd, J=2.8, 9.0 Hz), 7.56-7.68 (1H, m), 7.97 (1H, s)

MS(ESI$^+$) : 343[M+H]$^+$, 384[M+H+MeCN]$^+$

Example 112

5-[5-Amino-3-(2,5-difluorophenyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 0.97 (6H, d, J=6.8 Hz), 4.91 (1H, sept, J=6.8 Hz), 6.36 (1H, d, J=9.5 Hz), 6.73 (2H, brs), 7.21-7.30(3H, m), 7.44-7.52 (2H, m), 7.99 (1H, s)

MS(ESI$^+$) : 343[M+H]$^+$, 384[M+H+MeCN]$^+$

Example 113

5-[5-Amino-3-(2-furyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 1.22 (6H, d, J=7.0 Hz), 5.06 (1H, sept,

J=7.0 Hz), 6.38 (1H, d, J=9.0 Hz), 6.56 (1H, dd, J=1.8, 3.5 Hz), 6.65-6.66 (1H, m), 7.36 (3H, dd, J=2.8, 9.5 Hz), 7.58 (2H, d, J=2.5 Hz), 7.70 (1H, m), 7.87 (1H, s)

MS(ESI$^+$) : 297[M+H]$^+$, 338[M+H+MeCN]$^+$

Example 114

5-[5-Amino-3-(3-furyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 1.19 (6H, d, J=6.5 Hz), 5.04 (1H, sept, J=6.5 Hz), 6.4 (1H, d, J=12.0 Hz), 6.42 (1H, brs), 6.54 (2H, brs), 7.39 (1H, dd, J=2.5, 9.5 Hz), 7.59 (1H, d, J=2.5 Hz), 7.65-7.69 (2H, m), 7.84 (1H, brs)

MS(ESI$^+$) : 297[M+H]$^+$, 338[M+H+MeCN]$^+$

Example 115

5-[5-Amino-3-(2-thienyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 1.20 (6H, d, J=6.5 Hz), 5.06 (1H, sept, J=6.5 Hz), 6.4 (1H, d, J=9.5 Hz), 6.63 (2H, brs), 6.99-7.04 (2H, m), 7.36 (1H, dd, J=2.5, 9.5 Hz), 7.59 (1H, dd, J=2.0, 4.5 Hz), 7.68 (1H, d, J=2.0 Hz), 7.84 (1H, s)

MS(ESI$^+$) : 313[M+H]$^+$, 354[M+H+MeCN]$^+$

Example 116

5-[5-Amino-3-(3-thienyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 1.09 (6H, d, J=6.5 Hz), 4.97 (1H, sept, J=6.5 Hz), 6.35 (1H, d, J=9.5 Hz), 6.56 (2H, brs), 7.04 (1H,

dd, J=1.3, 5.0 Hz), 7.38-7.44 (2H, m), 7.51-7.58 (2H, m), 7.87 (1H, s)

MS(ESI$^+$) : 313[M+H]$^+$, 354[M+H+MeCN]$^+$

Example 117

5-[5-Amino-3-(5-methyl-2-thienyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 1.22 (6H, d, J=6.5 Hz), 2.41 (3H, s), 5.07 (1H, sept, J=6.5 Hz), 6.40 (1H, d, J=9.5 Hz), 6.57 (2H, brs), 6.69-6.70 (1H, m), 6.84 (1H, d, J=3.5 Hz), 7.35 (1H, dd, J=2.5, 9.0 Hz), 7.70 (1H, d, J=2.5 Hz), 7.79 (1H, s)

MS(ESI$^+$) : 327[M+H]$^+$, 368[M+H+MeCN]$^+$

Example 118

5-[5-Amino-3-(1*H*-pyrazol-4-yl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 1.20 (6H, d, J=6.5 Hz), 5.05 (1H, sept, J=6.5 Hz), 6.38 (1H, d, J=9.0 Hz), 6.45 (2H, brs), 7.34 (1H, dd, J=2.5, 9.0 Hz), 7.50-7.62 (3H, m), 7.77 (1H, s), 12.92 (1H, brs)

MS(ESI$^+$) : 319[M+Na]$^+$, 615[2M+Na]$^+$

Example 119

5-{5-Amino-3-[(E)-2-phenylvinyl]-2-pyrazinyl}-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 1.30 (6H, d, J=7.0 Hz), 5.13 (1H, sept, J=7.0 Hz), 6.49 (1H, d, J=9.5 Hz), 6.58 (2H, brs), 7.16 (1H, d, J=15.6 Hz), 7.29-7.40 (3H, m), 7.53-7.65 (4H, m), 7.74

(1H, d, J=2.0 Hz), 7.88 (1H, s)

MS(ESI$^+$) : 333[M+H]$^+$, 355[M+Na]$^+$, 687[2M+Na]$^+$

Example 120

5-[5-Amino-3-(4-fluorophenyl)-2-pyrazinyl]-1-methyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 3.40 (3H, s), 6.20 (1H, d, J=9.5 Hz), 6.62 (2H, brs), 7.01 (1H, dd, J=2.5, 9.5 Hz), 7.21 (1H, t, J=8.5 Hz), 7.46 (1H, dd, J=5.5, 8.5 Hz), 7.74 (1H, d, J=2.5 Hz), 7.90 (1H, s)

MS(ESI$^+$) : 297[M+H]$^+$, 319[M+Na]$^+$, 615[2M+Na]$^+$

Example 121

5-[5-Amino-3-(2-furyl)-2-pyrazinyl]-1-methyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 3.46 (3H, s), 6.33 (1H, d, J=9.5 Hz), 6.57 (1H, dd, J=1.5, 3.5 Hz), 6.65-6.68 (3H, m), 7.22 (1H, dd, J=2.5, 9.5 Hz), 7.69 (1H, s), 7.78 (1H, d, J=2.5 Hz), 7.85 (1H, s)

MS(ESI$^+$) : 269[M+H]$^+$, 291[M+Na]$^+$, 559[2M+Na]$^+$

Example 122

5-[5-Amino-3-(2-thienyl)-2-pyrazinyl]-1-methyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 3.46 (3H, s), 6.36 (1H, d, J=9.5 Hz), 6.64 (2H, brs), 6.99-7.07 (2H, m), 7.28 (1H, dd, J=2.5, 9.5 Hz), 7.60 (1H, d, J=3.5 Hz), 7.82 (1H, s), 7.85 (1H, d, J=2.5 Hz)

MS(ESI$^+$) : 307[M+Na]$^+$, 591[2M+Na]$^+$

Example 123

5-[5-Amino-3-(phenylethynyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 1.26 (6H, d, J=7.0 Hz), 5.06 (1H, t, J=7.0 Hz), 6.49 (1H, d, J=9.5 Hz), 6.75 (2H, brs), 7.43-7.54 (5H, m), 7.91 (1H, dd, J=2.5, 9.5 Hz), 7.95 (1H, s), 8.17 (1H, d, J=2.5 Hz)

MS(ESI$^+$) : 331[M+H]$^+$, 353[M+Na]$^+$, 683[2M+Na]$^+$

Example 124

5-[5-Amino-3-(2-fluorophenyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 0.92 (6H, d, J=7.0 Hz), 4.88 (1H, sept, J=7.0 Hz), 6.34 (1H, d, J=9.5 Hz), 6.67 (2H, brs), 7.15-7.60 (6H, m), 7.97 (1H, s)

MS(ESI$^+$) : 325[M+H]$^+$, 366[M+H+MeCN]$^+$

Example 125

5-[5-Amino-3-(3-fluorophenyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 1.00 (6H, d, J=6.8 Hz), 4.94 (1H, sept, J=6.8 Hz), 6.35 (1H, d, J=9.0 Hz), 6.68 (2H, brs), 7.28-7.48 (6H, m), 7.95 (1H, s)

MS(ESI$^+$) : 341[M+H]$^+$, 382[M+H+MeCN]$^+$

Example 126

5-[5-Amino-3-(3-chlorophenyl)-2-pyrazinyl]-1-isopropyl-

2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 1.00 (6H, d, J=6.8 Hz), 4.94 (1H, sept, J=6.8 Hz), 6.35 (1H, d, J=9.0 Hz), 6.68 (2H, brs), 7.28-7.48 (6H, m), 7.95 (1H, s)

MS(ESI$^+$) : 341[M+H]$^+$, 382[M+H+MeCN]$^+$

Example 127

5-[5-Amino-3-(4-chlorophenyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 1.00 (6H, d, J=6.8 Hz), 4.93 (1H, sept, J=6.8 Hz), 6.34 (1H, d, J=9.5 Hz), 6.65 (2H, brs), 7.25 (1H, d, J=2.5 Hz), 7.38-7.48 (5H, m), 7.93 (1H, s)

MS(ESI$^+$) : 341[M+H]$^+$, 382[M+H+MeCN]$^+$

Example 128

5-[5-Amino-3-(3,4-difluorophenyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 1.03 (6H, d, J=6.8 Hz), 4.96 (1H, sept, J=6.8 Hz), 6.35 (1H, d, J=9.5 Hz), 6.68 (2H, brs), 7.20-7.53 (6H, m), 7.95 (1H, s)

MS(ESI$^+$) : 343[M+H]$^+$, 384[M+H+MeCN]$^+$

Example 129

5-[5-Amino-3-(3,5-difluorophenyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 1.04 (6H, d, J=6.8 Hz), 4.96 (1H, sept, J=6.8 Hz), 6.37 (1H, d, J=9.0 Hz), 6.72 (2H, brs), 7.07-7.46 (5H, m), 7.97 (1H, s)

MS(ESI$^+$) : 343[M+H]$^+$, 384[M+H+MeCN]$^+$

Example 130

5-(5-Amino-3-phenyl-2-pyrazinyl)-1-methyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 3.38 (3H, s), 6.16 (1H, d, J=4.8 Hz), 6.60 (2H, brs), 6.99 (1H, dd, J=1.4, 4.8 Hz), 7.36-7.42 (5H, m), 7.72 (1H, d, J=1.4 Hz), 7.90 (1H, s)

Example 131

To a suspention of 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-(2-pyridyl)-2-pyrazinecarboxamide (52 mg) in dioxane (0.5 ml) was added an *aq.* NaOH (2*M*, 1 ml) and this solution was heated at 100°C for 4 hours. This reaction mixture was cooled to room temperature and the pH of this solution was adjusted to 2.5 with 2*N aq.* HCl. This solution was evaporated under reduced pressure to give yellow solid. A suspension of this yellow solid in 1,2-dichlorobenzene (2 ml) was heated at 200°C and stirred for 4 hours. This reaction mixture was cooled to room temperature. To this solution was added IPE and stirred at room temperature for 1 hour. The precipitate was collected by filtration and washed with IPE. The residual solid was placed on a column of silica-gel and eluted with $CHCl_3$ - MeOH - 28% *aq.* ammonia (15 : 1 : 0.1). The eluent was evaporated and the residue was purified by recrystallization from EtOAc - IPE to give 5-[5-amino-

3-(2-pyridyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone (5 mg) as a pale yellow crystal.

^{1}H-NMR(DMSO-d_6 δ) : 1.13 (6H, d, J=7.0 Hz), 5.18 (1H, t, J=7.0 Hz), 6.48 (1H, d, J=9.0 Hz), 7.29-7.38 (3H, m), 7.46 (1H, d, J=7.5 Hz), 7.75 (1H, dt, J=1.7, 7.5 Hz), 8.09 (1H, s), 8.71 (1H, d, J=4.5 Hz)

MS(ESI$^+$) : 308[M+H]$^+$, 349[M+H+MeCN]$^+$

The following 2 compounds were obtained in a similar manner to that of Example 131.

Example 132

5-[5-Amino-3-(3-pyridyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 0.98 (6H, d, J=7.0 Hz), 4.92 (1H, t, J=7.0 Hz), 6.35 (1H, d, J=9.5 Hz), 6.71 (2H, brs), 7.3 (1H, d, J=2.5 Hz), 7.38-7.46 (2H, m), 7.79 (1H, dt, J=2.5, 4.0 Hz), 7.97 (1H, s), 8.51 (1H, dd, J=1.5, 5.0 Hz), 8.56 (1H, d, J=1.5 Hz)

MS(ESI$^+$) : 308[M+H]$^+$, 349[M+H+MeCN]$^+$

Example 133

5-[5-Amino-3-(4-pyridyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 0.96 (6H, d, J=7.0 Hz), 4.92 (1H, t, J=7.0 Hz), 6.36 (1H, d, J=9.5 Hz), 6.74 (2H, brs), 7.25 (1H, d, J=2.5 Hz), 7.36-7.48 (3H, m), 7.99 (1H, brs), 8.56-8.59 (2H, m)

MS(ESI$^+$) : 308[M+H]$^+$, 349[M+H+MeCN]$^+$

Example 134

3-Amino-5-chloro-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-2-pyrazinecarboxamide (500 mg), (4-methoxyphenyl)boronic acid (740 mg), and $Pd(PPh_3)_4$ (56.3 mg) in 2*M* *aq.* Na_2CO_3 (3.25 ml) and dioxane (20 ml) was refluxed for 3 hours. Water (40 ml) and EtOAc (30 ml) were poured into the reaction mixture and the aqueous solution was extracted with EtOAc. The organic layer was washed with water and brine, and dried over $MgSO_4$. After filtration, the solvent was removed under reduced pressure. The residual solid was placed on a column of silica-gel and eluted with $CHCl_3$ - MeOH (97 : 3). The eluent was evaporated and the residue was suspended with IPE and filtrated to give yellow powder. To a suspension of this yellow powder in dioxane (0.5 ml) was added an *aq.* NaOH (2*M*, 1 ml) and this solution was heated at 100°C for 4 hours. This reaction mixture was cooled to room temperature and the pH of this solution was adjusted to 2.5 with 2*N* *aq.* HCl. This solution was evaporated under reduced pressure to give yellow solid. A suspension of this yellow solid in 1,2-dichlorobenzen (2 ml) was heated at 200°C and stirred for 4 hours. This reaction mixture was cooled to room temperature. To this solution was added IPE and stirred at room temperature for 1 hour. The precipitate was collected by filtration and

washed with IPE. The residual solid was placed on a column of silica-gel and eluted with $CHCl_3$ - MeOH (97 : 3). The eluent was evaporated and the residue was purified by GPC (Gel Permeation Chromatography) to give 5-[5-amino-3-(5-chloro-2-thienyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone (25 mg) and 5-[5-amino-3-(5'-chloro-2,2'-bithien-5-yl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone (26 mg) as yellow powder.

5-[5-Amino-3-(5-chloro-2-thienyl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 1.24 (6H, d, J=7.0 Hz), 5.08 (1H, sept, J=7.0 Hz), 6.43 (1H, d, J=9.0 Hz), 6.7 (2H, brs), 6.86 (1H, d, J=11.4 Hz), 7.02 (1H, d, J=4.0 Hz), 7.38 (1H, dd, J=2.5, 9.0 Hz), 7.77 (1H, d, J=2.5 Hz), 7.85 (1H, brs)

MS(ESI$^+$) : 347[M+H]$^+$, 388[M+H+MeCN]$^+$

5-[5-Amino-3-(5'-chloro-2,2'-bithien-5-yl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

^{1}H-NMR(DMSO-d_6 δ) : 1.24 (6H, d, J=6.5 Hz), 5.09 (1H, sept, J=6.5 Hz), 6.44 (1H, d, J=9.5 Hz), 6.69 (2H, brs), 6.93 (1H, d, J=3.5 Hz), 7.12-7.21 (3H, m), 7.40 (1H, dd, J=2.5, 9.5 Hz), 7.78 (1H, d, J=2.5 Hz), 7.85 (1H, s)

MS(ESI$^+$) : 429[M+H]$^+$, 470[M+H+MeCN]$^+$

Example 135

3-Amino-5-(4-fluorophenyl)-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-N-methyl-2-pyrazinecarboxamide

The title compound was obtained in a similar manner to that of Preparation 42.

^{1}H-NMR(DMSO-d_6 δ) : 0.98 (6H, d, J=7.0 Hz), 2.84 (3H, d, J=5.0 Hz), 4.92 (1H, sept, J=7.0 Hz), 6.39 (1H, d, J=9.0 Hz), 7.21-7.78 (8H, m), 8.68 (1H, d, J=5.0 Hz)

MS(ESI$^+$) : 382[M+H]$^+$, 404[M+Na]$^+$, 785[2M+Na]$^+$

Example 136

To a suspension of 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylic acid (350 mg) in MeOH (7.0 ml), was added thionyl chloride (0.146 m) dropwise under ice-bath cooling. After 1 hour stirring at the same temperature, the mixture was allowed to warm to room temperature. The mixture was stirred for 6 hours and then refluxed with stirring for 15 hours. After cooling, the solvent was removed under reduced pressure. Water was poured into the residue and the pH of the mixture was adjusted to 10 with 1*N aq.* NaOH. A precipitate was isolated by filtration, washed with water, and dried in vacuo to give methyl 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylate (244 mg).

^{1}H-NMR(DMSO-d_6 δ) : 0.91 (6H, d, J=6.8 Hz), 3.89 (3H, s), 4.89 (1H, qq, J=6.8, 6.8 Hz), 6.41 (1H, d, J=9.3 Hz), 7.21 (1H, d, J=2.4 Hz), 7.30-7.50 (7H, m), 7.56 (1H, dd, J=2.4, 9.3 Hz)

MS(ESI$^+$) : 365[M+H]$^+$, 387[M+Na]$^+$

Example 137

Under ice-bath cooling, methylmagnesium chloride (3*M* solution, 0.46 ml) was added to a suspension of methyl 3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinecarboxylate (100 mg) in THF (10 ml). After 7.5 hours stirring at the same temperature, *sat. aq.* ammonium chloride solution (1 ml) was poured into the mixture. Water and EtOAc were poured into the mixture and the organic layer was separated, washed with water and brine, and dried over $MgSO_4$. The solvent was removed under reduced pressure. The residue was recrystallized from MeOH-IPE and dried under reduced pressure to give 5-[5-amino-6-(1-hydroxy-1-methylethyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone (41 mg).

^{1}H-NMR(DMSO-d_6 δ) : 0.93 (6H, d, J=6.8 Hz), 1.56 (6H, s), 4.89 (1H, qq, J=6.8, 6.8 Hz), 5.76 (1H, brs), 6.37 (1H, d, J=9.3 Hz), 6.59 (2H, brs), 7.17 (1H, d, J=2.4 Hz), 7.20-7.50 (5H, m), 7.53 (1H, dd, J=2.4, 9.3 Hz)

MS(ESI$^+$) : 365[M+H]$^+$

Example 138

To a solution of 5-(6-acetyl-5-amino-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (82 mg) in THF - MeOH (1 : 1, 2.0 ml), was added sodium borohydride (8.9 mg). The mixture was stirred st room temperature for 4 hours.

1*N* HCl (0.05 ml) was poured into the mixtre. Water and EtOAc were poured into the mixture and the organic layer was separated, washed with water and brine, and dried over $MgSO_4$. The solvent was removed under reduced pressure. The residue was purified by column chromatography. The desired product was recrystallized from EtOH and dried in vacuo to give 5-[5-amino-6-(1-hydroxyethyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone (16 mg).

^{1}H-NMR(DMSO-d_6 δ) : 0.93 (3H, d, J=6.7 Hz), 0.94 (3H, d, J=6.7 Hz), 1.46 (3H, d, J=6.5 Hz), 4.70-5.00 (2H, m), 5.57 (1H, d, J=5.4 Hz), 6.35 (1H, d, J=9.4 Hz), 6.40 (2H, brs), 7.18 (1H, d, J=2.5 Hz), 7.40 (5H, m), 7.53 (1H, dd, J=2.5, 9.4 Hz)

MS(ESI$^+$) : 351[M+H]$^+$

Example 139

Under ice-bath cooling, NaH (60% pure, 18 mg) was added to a suspension of 5-[5-amino-6-(hydroxymethyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone (100 mg) in DMF (1.0 ml). After 10 minute stirring, MeI (127 mg) was added to the mixture. After 10 minutes stirring at the same temperature, the mixture was allowed to warm to 25°C. After 3.5 hours stirring, EtOAc and water were poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over $MgSO_4$. The solvent was removed under reduced pressure and the residue was purified

by column chromatography, triturated with IPE , and dried in vacuo to give 5-[5-amino-6-(methoxymethyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone (40 mg).

^{1}H-NMR(DMSO-d_6 δ) : 0.93 (6H, d, J=6.7 Hz), 3.36 (3H, s), 4.53 (2H, s), 4.89 (1H, qq, J=6.7, 6.7 Hz), 6.36 (1H, d, J=9.4 Hz), 6.41 (1H, brs), 7.17 (1H, d, J=2.5 Hz), 7.2-7.5 (4H, m), 7.50 (1H, dd, J=2.5, 9.4 Hz)

MS(ESI$^+$) : 351[M+H]$^+$, 373[M+Na]$^+$

Example 140

5-{5-Amino-6-[(benzyloxy)methyl]-3-phenyl-2-pyrazinyl}-1-isopropyl-2(1*H*)-pyridone

The title compound was obtained in a similar manner to that of Preparation 139.

^{1}H-NMR(DMSO-d_6 δ) : 0.93 (6H, d, J=6.8 Hz), 4.62 (2H, s), 4.67 (2H, s), 4.89 (1H, qq, J=6.8, 6.8 Hz), 6.35 (1H, d, J=9.4 Hz), 6.45 (2H, brs), 7.18 (1H, d, J=2.4 Hz), 7.20-7.40 (10H, m), 7.49 (1H, dd, J=2.4, 9.4 Hz)

MS(ESI$^+$) : 427[M+H]$^+$, 449[M+Na]$^+$

Example 141

Under ice-bath cooling, N-bromosuccinimide (1.83 g) was added to a solution of 5-(5-amino-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (3.0 g) in DMF (90 ml). The mixture was stirred at the same temperature for 2 hours. Water and CH_2Cl_2 were poured into the mixture and the organic layer was separated, washed with *sat. aq.* sodium

thiosulfate solution, *sat. aq.* $NaHCO_3$ solution, water, and brine, and dried over $MgSO_4$. The solvent was removed under reduced pressure. The residue was purified by column chromatography (silica-gel, toluene - EtOAc), recrystallized from EtOH, and dried in vacuo to give 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (3.0 g).

^{1}H-NMR(DMSO-d_6 δ) : 0.93 (6H, d, J=6.8 Hz), 4.88 (1H, qq, J=6.8, 6.8 Hz), 6.35 (1H, d, J=9.4 Hz), 6.89 (2H, brs), 7.20 (1H, d, J=2.5 Hz), 7.30-7.50 (6H, m)

MS(ESI$^+$) : 385[M+H]$^+$, 407[M+Na]$^+$

Example 142

To a suspension of 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (100 mg) and $Pd(PPh_3)_4$ (15 mg) in THF (1.0 ml), was added a solution of methylzinc chloride in THF (2.0*M*, 0.75 ml). The mixture was stirred at 25°C for 7.5 hours and then heated at 60°C for 1.5 hours. After cooling, EtOAc and water were poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over $MgSO_4$. The solvent was removed under reduced pressure. The residue was crystallized form MeOH - IPE and dried in vacuo to give 5-(5-amino-6-methyl-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (95 mg).

^{1}H-NMR(DMSO-d_6 δ) : 0.94 (6H, d, J=6.8 Hz), 2.38 (3H, s),

4.89 (1H, qq, J=6.8, 6.8 Hz), 6.33 (1H, d, J=9.4 Hz), 6.38 (2H, s), 7.15 (1H, d, J=2.4 Hz), 7.20-7.50 (5H, m), 7.49 (1H, dd, J=2.4, 9.4 Hz)

MS(ESI$^+$) : 321$[M+H]^+$, 343$[M+Na]^+$

Example 143

A mixture of 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (100 mg), phenylboronic acid (79 mg), $Pd(PPh_3)_4$ (9 mg), a solution of Na_2CO_3 (110 mg) in water (0.8 ml) and dioxane (2.0 ml) was heated at 90°C with stirring for 1 hour. After cooling, EtOAc and water were poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over $MgSO_4$. The solvent was removed under reduced pressure. The residue was recrystallized from MeOH - IPE and dried in vacuo to give 5-(5-amino-3,6-diphenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (84 mg).

^{1}H-NMR(DMSO-d_6 δ) : 0.94 (6H, d, J=6.8 Hz), 4.90 (1H, qq, J=6.8, 6.8 Hz), 6.30-6.40 (3H, m), 7.24 (dH, d, J=2.0 Hz), 7.30-7.70 (9H, m), 7.80-7.90 (2H, m)

MS(ESI$^+$) : 383$[M+H]^+$, 405$[M+Na]^+$

Example 144

5-[5-Amino-6-(2-furyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

The title compound was obtained in a similar manner to that of Preparation 143.

^{1}H-NMR(DMSO-d_6 δ) : 0.95 (6H, d, J=6.8 Hz), 4.91 (1H, qq, J=6.8, 6.8 Hz), 6.38 (1H, d, J=9.4 Hz), 6.60-6.80 (3H, m), 7.19 (1H, d, J=3.4 Hz), 7.27 (1H, d, J=2.4 Hz), 7.30-7.50 (5H, m), 7.59 (1H, dd, J=2.4, 9.4 Hz), 7.89 (1H, d, J=1.1 Hz)

MS(ESI$^+$) : 373$[M+H]^+$, 395$[M+Na]^+$

Example 145

A mixture of 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (100 mg), acrylamide (55 mg), $Pd(OAc)_2$ (3 mg), tris(2-methylphenyl)phosphine (8 mg), NEt_3 (0.11 ml), and DMF (1.0 ml) was heated with stirring at 60°C for 1 hour and then at 90°C for 5 hours. After cooling, EtOAc and water were poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over $MgSO_4$. The solvent was removed under reduced pressure. The residue was recrystallized from EtOAc and dried in vacuo to give (2E)-3-[3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinyl]acrylamide (70 mg).

^{1}H-NMR(DMSO-d_6 δ) : 0.93 (6H, d, J=6.8 Hz), 4.90 (1H, qq, J=6.8, 6.8 Hz), 6.40 (1H, d, J=9.4 Hz), 6.81 (2H, brs), 7.08 (1H, d, J=14.9 Hz), 7.10-7.20 (2H, m), 7.20-7.50 (5H, m), 7.62 (1H, dd, J=2.5, 9.3 Hz), 7.70 (1H, brs), 7.75 (1H, d, J=14.9 Hz)

MS(ESI$^+$) : 376[M+H]$^+$, 398[M+Na]$^+$

Example 146

(2E)-3-[3-amino-6-(1-isopropyl-6-oxo-1,6-dihydro-3-pyridyl)-5-phenyl-2-pyrazinyl]-N,N-dimethylacrylamide

The title compound was obtained in a similar manner to that of Preparation 145.

^{1}H-NMR(DMSO-d_6 δ) : 0.96 (6H, d, J=6.7 Hz), 2.96 (3H, s), 3.16 (3H, s), 4.92 (1H, qq, J=6.7, 6.7 Hz), 6.36 (1H, d, J=9.4 Hz), 6.84 (2H, brs), 7.30-7.60 (8H, m), 7.79 (1H, d, J=14.6 Hz)

MS(ESI$^+$) : 404[M+H]$^+$, 426[M+Na]$^+$

Example 147

To a mixture of 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (500 mg), ethynyl(trimethyl)silane (255 mg), $PdCl_2(PPh_3)_2$ (46 mg), CuI (12 mg), and CH_2Cl_2 (10 ml), was added NEt_3 (0.2 ml) under ice-bath cooling. The mixture was allowed to warm to 25°C and stirred for 15 hours. Water and EtOAc were poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over $MgSO_4$. The solvent was removed under reduced pressure. The residue was purified by column chromatography (silica-gel; CH_2Cl_2 - MeOH), recrystallized from EtOH, and dried in vacuo to give 5-{5-amino-3-phenyl-6-[(trimethylsilyl)ethynyl]-2-pyrazinyl}-1-isopropyl-2(1*H*)-pyridone (373 mg).

^{1}H-NMR(DMSO-d_6 δ) : 0.29 (9H, s), 0.94 (6H, d, J=6.7 Hz), 4.89 (1H, qq, J=6.7, 6.7 Hz), 6.34 (1H, d, J=9.4 Hz), 6.70 (2H, brs), 7.21 (1H, d, J=2.4 Hz), 7.30-7.50 (5H, m), 7.47 (1H, dd, J=2.5, 9.4 Hz)

MS(ESI$^+$) : 403[M+H]$^+$, 425[M+Na]$^+$

Example 148

A mixture of 5-{5-amino-3-phenyl-6-[(trimethylsilyl)ethynyl]-2-pyrazinyl}-1-isopropyl-2(1*H*)-pyridone (300 mg) and *sat.* K_2CO_3 in MeOH (4.5 ml) was stirred at 25°C for 3 hours. Water and EtOAc were poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over $MgSO_4$. The solvent was removed under reduced pressure. The residue was purified by short column (silica-gel; CH_2Cl_2) and recrystallized from EtOH to give 5-(5-amino-6-ethynyl-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (100 mg).

^{1}H-NMR(DMSO-d_6 δ) : 0.95 (6H, d, J=6.8 Hz), 4.71 (1H, s), 4.89 (1H, qq, J=6.8, 6.8 Hz), 6.34 (1H, d, J=9.3 Hz), 6.75 (2H, brs), 7.22 (1H, d, J=2.5 Hz), 7.30-7.50 (6H, m)

MS(ESI$^+$) : 331[M+H]$^+$, 353[M+Na]$^+$

Example 149

A mixture of 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (100 mg), sodium methoxide (70 mg), CuI (5 mg) in NMP (1.0 ml) was heated

at 100°C for 2.5 hours. After cooling, EtOAc and water were poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over $MgSO_4$. The solvent was removed under reduced pressure. The residue was recrystallized from MeOH - IPE to give 5-(5-amino-6-methoxy-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (58 mg).

^{1}H-NMR(DMSO-d_6 δ) : 0.94 (6H, d, J=6.7 Hz), 3.98 (3H, s), 4.90 (1H, qq, J=6.7, 6.7 Hz), 6.35 (1H, d, J=9.4 Hz), 6.49 (2H, brs), 7.19 (1H, d, J=9.4 Hz), 7.20-7.40 (5H, m), 7.52 (1H, dd, J=2.5, 9.4 Hz)

MS(ESI$^+$) : 337[M+H]$^+$, 359[M+Na]$^+$

Example 150

A mixture of 5-(5-amino-6-methoxy-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (80 mg), *conc.* HCl (0.8 ml), and dioxane (1.6 ml) was heated with stirring at 100°C for 3 hours. After cooling, the pH of the mixture was adjusted to 8 and a generated precipitate was isolated by filtration and dired in vacuo to give 5-(5-amino-6-hydroxy-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (36 mg).

^{1}H-NMR(DMSO-d_6 δ) : 1.08 (6H, d, J=6.8 Hz), 4.94 (1H, qq, J=6.8, 6.8 Hz), 6.26 (1H, d, J=9.4 Hz), 6.76 (2H, brs), 7.13 (1H, dd, J=2.2, 9.4 Hz), 7.1-7.3 (5H, m), 7.46 (1H, d, J=2.2 Hz), 11.91 (1H, brs)

MS(ESI$^+$) : 323[M+H]$^+$, 345[M+Na]$^+$

Example 151

To a solution of phenol (147 mg) in NMP (1.0 ml), was added 60% NaH (52 mg) under ice-bath cooling. After 5 minutes stirring, 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (100 mg) was added to the mixture at the same temperature. And then the mixture was heated at 100°C with stirring for 5.5 hours. After cooling, EtOAc and water were poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over $MgSO_4$. The solvent was removed under reduced pressure. The residue was recrystallized from MeOH - IPE to give 5-(5-amino-6-phenoxy-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (88 mg).

^{1}H-NMR(DMSO-d_6 δ) : 0.90 (6H, d, J=6.8 Hz), 4.86 (1H, qq, J=6.8, 6.8 Hz), 6.23 (1H, d, J=10.1 Hz), 7.15 (2H, m), 7.20-7.50 (10H, m)

MS(ESI$^+$) : 399[M+H]$^+$, 421[M+Na]$^+$

Example 152

A mixture of 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (100 mg) and a solution of methylamine in THF (2.0*M*, 1.0 ml) was heated at 100°C with stirring for 20 hours in a sealed tube. After cooling, the solvent was removed under reduced pressure and the residue was recrystallized from MeOH - IPE to give

5-[5-amino-6-(methylamino)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone (13 mg). The filtrate was concentrated in vacuo, and the residue was rinsed with MeOH - IPE to give the desired product (60 mg).

^{1}H-NMR(DMSO-d_6 δ) : 0.94 (6H, d, J=6.7 Hz), 2.93 (3H, d, J=4.4 Hz), 4.90 (1H, qq, J=6.7, 6.7 Hz), 6.11 (2H, brs), 6.33 (1H, d, J=9.3 Hz), 6.49 (1H, m), 7.19 (1H, d, J=2.4 Hz), 7.10-7.40 (5H, m), 7.52 (1H, dd, J=2.4, 9.4 Hz)

MS(ESI$^+$) : 336[M+H]$^+$, 358[M+Na]$^+$

Example 153

A mixture of 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (100 mg), morpholine (113 mg), and NMP (1.0 ml) was heated at 150°C with stirring for 1 day. After cooling, EtOAc and water were poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over $MgSO_4$. The solvent was removed under reduced pressure, and the residue was recrystallized from MeOH - IPE and dried in vacuo to give 5-[5-amino-6-(4-morpholinyl)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone (84 mg).

^{1}H-NMR(DMSO-d_6 δ) : 0.94 (6H, d, J=6.7 Hz), 3.10-3.20 (4H, m), 3.70-3.90 (4H, m), 4.90 (1H, qq, J=6.7, 6.7 Hz), 6.22 (2H, brs), 6.35 (1H, d, J=9.4 Hz), 7.19 (1H, d, J=2.4 Hz), 7.20-7.40 (5H, m), 7.54 (1H, dd, J=2.4, 9.4 Hz)

MS(ESI$^+$) : 392[M+H]$^+$, 414[M+Na]$^+$

Example 154

A mixture of 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (100 mg), dimethylamine hydrochloride (106 mg), N,N-diisopropylethylamine (201 mg) in NMP (1.0 ml) was heated at 150°C with stirring for 65 hours. After cooling, EtOAc and water were poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over $MgSO_4$. The solvent was removed under reduced pressure. The residue was recrystallized from MeOH - IPE and dried in vacuo to give 5-[5-amino-6-(dimethylamino)-3-phenyl-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone (8 mg).

^{1}H-NMR(DMSO-d_6 δ) : 0.94 (6H, d, J=7.0 Hz), 2.83 (6H, s), 4.90 (1H, qq, J=7.0, 7.0 Hz), 6.16 (2H, brs), 6.34 (1H, d, J=9.5 Hz), 7.20 (1H, d, J=2.5 Hz), 7.20-7.40 (5H, m), 7.54 (1H, dd, J=2.5, 9.5 Hz)

MS(ESI$^+$) : 350$[M+H]^+$, 372$[M+Na]^+$

Example 155

To a solution of pyrazole (106 mg) in NMP (1.0 ml), was added 60% NaH (52 mg) under ice-bath cooling. After 5 minutes stirring, 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (100 mg) was added to the mixture. And then the mixture was heated at 100°C with stirring for 2 hours. After cooling, EtOAc and water were poured into the mixture, and the organic layer

was separated, washed with water and brine, and dried over $MgSO_4$. The solvent was removed under reduced pressure, and the residue was recrystallized from MeOH and dried in vacuo to give 5-[5-amino-3-phenyl-6-(1*H*-pyrazol-1-yl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone (60 mg).

^{1}H-NMR(DMSO-d_6 δ) : 0.98 (6H, d, J=6.8 Hz), 4.92 (1H, qq, J=6.8, 6.8 Hz), 6.38 (1H, d, J=9.4 Hz), 6.68 (1H, m), 7.3-7.5 (6H, m), 7.5-7.7 (3H, m), 7.94 (1H, m), 8.78 (1H, m)

MS(ESI$^-$) : 371[M-H]$^-$

Example 156

5-[5-amino-3-phenyl-6-(1*H*-pyrrol-1-yl)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone

The title compound was obtained in a similar manner to that of Preparation 155.

^{1}H-NMR(DMSO-d_6 δ) : 0.95 (6H, d, J=6.8 Hz), 4.90 (1H, qq, J=6.8, 6.8 Hz), 6.3-6.4 (3H, m), 6.49 (2H, brs), 7.28 (1H, d, J=2.4 Hz), 7.30-7.50 (7H, m), 7.53 (1H, dd, J=2.4, 9.4 Hz)

MS(ESI$^+$) : 372[M+H]$^+$, 394[M+Na]$^+$

Example 157

To a suspension of 60% NaH (52 mg) in NMP (1.0 ml), was added thiophenol (143 mg) under ice-bath cooling. After 10 minute stirring, 5-(5-amino-6-bromo-3-phenyl-2-pyrazinyl)-1-isopropyl-2(1*H*)-pyridone (100 mg) was added to the mixture at the same temperature. The mixture

was stirred at the same temperature for 10 minutes and then allowed to warm to 25°C. After 2 hours stirring, the mixture was heated at 100°C for 1 hour. After cooling, EtOAc and water were poured into the mixture, and the organic layer was separated, washed with water and brine, and dried over $MgSO_4$. The solvent was removed under reduced pressure. The residue was recrystallized from MeOH - IPE to give 5-[5-amino-3-phenyl-6-(phenylthio)-2-pyrazinyl]-1-isopropyl-2(1*H*)-pyridone (93 mg).

^{1}H-NMR(DMSO-d_6 δ) : 0.93 (6H, d, J=6.8 Hz), 4.87 (1H, qq, J=6.8, 6.8 Hz), 6.18 (1H, d, J=9.4 Hz), 6.62 (2H, brs), 7.06 (1H, dd, J=2.4, 9.4 Hz), 7.17 (1H, d, J=2.4 Hz), 7.3-7.5 (8H, m), 7.5-7.6 (2H, m)

MS(ESI$^+$) : 415[M+H]$^+$, 437[M+Na]$^+$

CLAIMS

1. A pyrazine derivative shown by the following formula (I):



(I)

wherein

R^1 is  or 

wherein

R^6 is hydrogen, or optionally substituted lower alkyl;

R^7 is hydrogen or halogen;

R^8 is lower alkyl;

R^2 is hydrogen; hydroxy; halogen; cyano; or lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, aryloxy, arylthio, acyl, aryl, heterocyclic group or amino, each of which is optionally substituted by substituent(s);

R^3 and R^4 are independently hydrogen, lower alkyl or acyl; and

R^5 is lower alkyl, lower alkenyl, lower alkynyl, cyano, aryl or heterocyclic group, each of which is optionally substituted by substituent(s);

or a salt thereof.

2. The compound of claim 1, wherein

R^1 is  ;

wherein

R^6 is hydrogen, lower alkyl, aryl(lower)alkyl, heteroaryl(lower)alkyl;

R^7 is hydrogen or halogen;

R^2 is hydrogen, halogen, cyano, optionally substituted lower alkyl, optionally substituted lower alkynyl, lower alkoxy, aryloxy, arylthio, carbamoyl, carboxy, protected carboxy or optionally substituted amino;

R^3 and R^4 are independently hydrogen or lower alkyl; and

R^5 is aryl or heteroaryl each of which is optionally substituted by one or more substituent(s);

or a salt thereof.

3. The compound of claim 2, wherein

R^2 is hydrogen, halogen, cyano, hydroxylated(lower)alkyl, lower alkynyl, lower alkoxy, aryloxy, arylthio, carboxy, esterified carboxy, carbamoyl, amidated carboxy, amino or mono- or di-(lower)alkylamino;

R^3 and R^4 are independently hydrogen;

R^5 is aryl or heteroaryl, each of which is optionally substituted by one or more substituent(s) selected from the group consisting of halogen and lower alkoxy;

R^6 is hydrogen or lower alkyl; and

R^7 is hydrogen;

or a salt thereof.

4. The compound of claim 3, wherein

R^2 is hydrogen, bromo, cyano, hydroxymethyl, hydroxyethyl, hydroxypropyl, ethynyl, methoxy, ethoxy, propoxy, phenyloxy, phenylthio, carboxy, carbamoyl, mono- or di-methylaminocarbonyl, pyridylmethylaminocarbonyl, hydroxymethylaminocarbonyl or mono- or di-methylamino;

R^3 and R^4 are independently hydrogen;

R^5 is phenyl, pyridyl, furyl, thienyl, pyrrolyl or pyrazolyl, each of which is optionally substituted by one or more substituent(s) selected from the group consisting of fluoro, chloro and methoxy;

R^6 is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl or *t*-butyl ; and

R^7 is hydrogen;

or a salt thereof.

5. The compound of claim 4, wherein

R^2 is hydrogen, cyano, ethynyl, methoxy, phenyloxy, phenylthio, carboxy, carbamoyl or methylamino; and

R^5 is phenyl, furyl or thienyl, each of which is optionally substituted by one or more substituent(s) selected from the group consisting of fluoro, chloro and methoxy;

or a salt thereof.

6. The compound of claim 5, wherein

R^2 is hydrogen, cyano, carboxy, carbamoyl or methylamino;

R^5 is phenyl which is optionally substituted by one or more fluoro; and

R^6 is hydrogen, methyl, ethyl or isopropyl;

or a salt thereof.

7. A process for preparing the pyrazine compound of the following formula (I):



(I)

wherein R^1, R^2, R^3, R^4 and R^5 are each as defined in claim 1, or a salt thereof;

which comprises

(1) reacting of a compound of the formula (II):



(II)

wherein R^1, R^2, R^3 and R^4 are each as defined above, and

Hal is a halogen atom;

or a salt thereof,

with a compound of the formula (III) :

R^5-Z (III)

wherein

R^5 is as defined above, and

Z is hydrogen, an alkali metal (e.g. lithium, sodium, potassium, etc.), $SnBu_3$, BW_2 or Met-Hal;

wherein BW_2 is a part of organoboron compound such as $B(OH)_2$, $B(CHCH_3CH(CH_3)_2)_2$, tetramethyl-1,3,2-dioxaborolan-2-yl, 9-borabicyclo[3.3.1]nonanyl, or the like; and

Met-Hal is a part of metalhalide compound such as MgBr, ZnCl, or the like;

or a salt thereof,

to give a compound of the formula (I):



(I)

wherein R^1, R^2, R^3, R^4 and R^5 are each as defined above,

or a salt thereof,

(2) hydrolyzing of a compound of the formula (Ia)



(Ia)

wherein R^3, R^4 and R^5 are each as defined above, and R^8 is as defined in claim 1, or a salt thereof,

to give a compound of the formula (Iba):



(Iba)

wherein R^3, R^4 and R^5 are each as defined above, and R^9 is cyano, carbamoyl or carboxy;

or a salt thereof,

(3) alkylating to a nitrogen atom of a compound of the formula (Ib):



(Ib)

wherein R^2, R^3, R^4 and R^5 are each as defined above, or a salt thereof,

with a compound of the formula (IV):

$$R^{10}\text{-}Y \quad (IV)$$

wherein R^{10} is lower alkyl, aryl(lower)alkyl or heteroaryl(lower)alkyl, each of which is

optionally substituted by one or more suitable substituent(s), and

Y is a leaving group;

or a salt thereof,

to give a compound of the formula (Ic):



(Ic)

wherein R^2, R^3, R^4, R^5 and R^{10} are each as defined above, or a salt thereof,

(4) hydrolyzing of a compound of the formula (Id):



(Id)

wherein R^1, R^3, R^4 and R^5 are each as defined above, or a salt thereof,

to give a compound of the formula (Ie):



(Ie)

wherein R^1, R^3, R^4 and R^5 are each as defined above, or a salt thereof,

(5) decarboxylating of a compound (Ie) or a salt thereof above to give a compound of the formula (If):



(If)

wherein R^1, R^3, R^4 and R^5 are each as defined above, or a salt thereof,

(6) halogenating of a compound (If) or a salt thereof above to give a compound of the formula (Ih):



(Ih)

wherein R^1, R^3, R^4, R^5 and Hal are each as defined above, or a salt thereof,

(7) reacting of a compound (Ih) or a salt thereof above with a compound of the formula (V):

$$R^{13}\text{-}Z \qquad (V)$$

wherein Z is defined above, and

R^{13} is lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, aryloxy, arylthio, acyl, aryl, heterocyclic group or amino, each of which is optionally substituted by substituent(s);

or a salt thereof,

to give a compound of the formula (Ij):



(Ij)

wherein R^1, R^3, R^4, R^5 and R^{13} are each as defined above, or a salt thereof,

(8) reacting of a compound of the formula (XI):



(XI)

wherein R^1 is as defined above, or a salt thereof, with aminomalonitrile,

to give a compound of the formula (XII):



(XII)

wherein R^1 and R^2 are each as defined above, or a salt thereof,

(9) halogenating of a compound of the formula (XV):



(XV)

wherein R^1, R^2, R^3 and R^4 are each as defined above, or a salt thereof,

with a compound of the formula (XVI):

$$PO(Hal)_3 \quad (XVI)$$

wherein Hal is as defined above,

to give a compound (II) or a salt thereof above.

8. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof

in admixture with a pharmaceutically acceptable carrier.

9. A method for preventing or treating a disease selected from the group consisting of depression, dementia, Parkinson's disease, anxiety, pain, cerebrovascular disease, heart failure, hypertension, circulatory insufficiency, post-resuscitation, asystole, bradyarrhythmia, electro-mechanical dissociation, hemodynamic collapse, SIRS (systemic inflammatory response syndrome), multiple organ failure, renal failure (renal insufficiency), renal toxicity, nephrosis, nephritis, edema, obesity, bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, ulcer, pancreatitis, Meniere's syndrome, anemia, dialysis-induced hypotension, constipation, ischemic bowel disease, ileus, myocardial infarction, thrombosis, obstruction, arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient ischemic attack and angina pectoris, which comprises administering the compound of claim 1 or a pharmaceutically acceptable salt thereof to a human being or an animal.

10. A method for preventing or treating a disease selected from the group consisting of depression, dementia, Parkinson's disease, anxiety, pain, cerebrovascular disease, Meniere's syndrome and cerebral infarction,

which comprises administering any of the compound of claim 1 to 7 or a pharmaceutically acceptable salt thereof to a human being or an animal.

11. A method for preventing or treating a disease selected from the group consisting of depression, dementia, Parkinson's disease and anxiety, which comprises administering any of the compound of claim 1 or a pharmaceutically acceptable salt thereof to a human being or an animal

12. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof as a medicament.

13. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof as an adenosine antagonist.

14. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof as an A_1 receptor and A_2 receptor dual antagonist.

15. A process for preparing a pharmaceutical composition which comprises admixing the compound of claim 1 or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable carrier.

16. Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof for the production of a pharmaceutical composition for the therapy of diseases on which an adenosine antagonist is therapeutically effective.

17. A method for evaluation of adenosine antagonism which comprises use of compound of claim 1 or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP2004/016193

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D401/04 C07D401/14 C07D409/14 C07D405/14 A61K31/4965

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 1 308 441 A (EISAI CO., LTD) 7 May 2003 (2003-05-07) examples 103a; 103b, 182, 183; table page 55, compounds 3-8, table page 60, compounds 112-114; table page 63, compounds 154-156 & WO 02/14282 A (EISAI CO., LTD; HARADA, HITOSHI; ASANO, OSAMU; MIYAZAWA, SHUHEI; UEDA,) 21 February 2002 (2002-02-21) cited in the application	1-17
Y	WO 00/25791 A (SMITHKLINE BEECHAM CORPORATION; ADAMS, JERRY, L; BOEHM, JEFFREY, C; HA) 11 May 2000 (2000-05-11) overlap; claims; pages 5, 11 and 26	1-17

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
17 March 2005	24/03/2005

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Frelon, D

Form PCT/ISA/210 (second sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP2004/016193

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 01/60806 A (NEUROGEN CORPORATION; YOON, TAEYOUNG; GE, PING; HORVATH, RAYMOND, F; D) 23 August 2001 (2001-08-23) overlap; pages 1-2; table I page 46, examples 3,10,14; table II page 55, example 46o-c, page 57, example 46j-k, page 59, examples 47m-n; table III page 74, examples 62z	1-17
Y	WO 03/045924 A (PHARMACIA & UPJOHN COMPANY; VERHOEST, PATRICK, R; HOFFMAN, ROBERT, L;) 5 June 2003 (2003-06-05) overlap; pages 6, 73 and 74	1-17
Y	WO 01/62233 A (F. HOFFMANN LA ROCHE AG) 30 August 2001 (2001-08-30) abstract; claims	1-17
A,P	WO 2004/016605 A (FUJISAWA PHARMACEUTICAL CO., LTD; AKAHANE ATSUSHI) 26 February 2004 (2004-02-26) the whole document	1-17
A	US 4 072 746 A (LESHER ET AL) 7 February 1978 (1978-02-07) abstract; claims	1-17
A	US 4 313 951 A (LESHER ET AL) 2 February 1982 (1982-02-02) abstract; claims	1-17

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2004/016193

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

see FURTHER INFORMATION sheet PCT/ISA/210

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claims 9-14 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
Although claim 17 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/JP2004/016193

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 1308441 A	07-05-2003	AU	7774101 A	25-02-2002
		CA	2417846 A1	30-01-2003
		EP	1308441 A1	07-05-2003
		MX	PA03001136 A	24-06-2003
		NO	20030637 A	10-04-2003
		US	2004006082 A1	08-01-2004
		CN	1446202 A	01-10-2003
		WO	0214282 A1	21-02-2002
		ZA	200300482 A	10-05-2004
WO 0214282 A	21-02-2002	AU	7774101 A	25-02-2002
		CA	2417846 A1	30-01-2003
		CN	1446202 A	01-10-2003
		EP	1308441 A1	07-05-2003
		WO	0214282 A1	21-02-2002
		MX	PA03001136 A	24-06-2003
		NO	20030637 A	10-04-2003
		US	2004006082 A1	08-01-2004
		ZA	200300482 A	10-05-2004
WO 0025791 A	11-05-2000	AT	258055 T	15-02-2004
		AU	1909200 A	22-05-2000
		DE	69914357 D1	26-02-2004
		DE	69914357 T2	11-11-2004
		EP	1126852 A1	29-08-2001
		ES	2212657 T3	16-07-2004
		JP	2002528506 T	03-09-2002
		WO	0025791 A1	11-05-2000
		US	2004014973 A1	22-01-2004
		US	6548503 B1	15-04-2003
WO 0160806 A	23-08-2001	AU	3849401 A	27-08-2001
		BG	106968 A	30-04-2003
		BR	0108363 A	10-02-2004
		CA	2398937 A1	23-08-2001
		CN	1400970 A	05-03-2003
		CZ	20022739 A3	12-02-2003
		EE	200200453 A	15-12-2003
		EP	1255740 A2	13-11-2002
		EP	1500653 A1	26-01-2005
		HR	20020747 A2	31-12-2004
		HU	0301573 A2	29-12-2003
		JP	2004500383 T	08-01-2004
		MX	PA02007868 A	10-02-2003
		NO	20023869 A	11-09-2002
		SK	11542002 A3	04-03-2003
		WO	0160806 A2	23-08-2001
		US	2003018035 A1	23-01-2003
		ZA	200206103 A	20-08-2003
WO 03045924 A	05-06-2003	AU	2002343557 A1	10-06-2003
		BR	0214309 A	13-10-2004
		CA	2467870 A1	05-06-2003
		EP	1446387 A1	18-08-2004
		WO	03045924 A1	05-06-2003
		US	2003144297 A1	31-07-2003
		US	2005049257 A1	03-03-2005

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/JP2004/016193

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0162233 A	30-08-2001	AU 5464301 A	03-09-2001
		BR 0108611 A	06-05-2003
		CA 2398274 A1	30-08-2001
		CN 1438890 A	27-08-2003
		CZ 20023199 A3	14-05-2003
		WO 0162233 A2	30-08-2001
		EP 1261327 A2	04-12-2002
		HR 20020673 A2	31-12-2004
		HU 0300029 A2	28-05-2003
		JP 2003523380 T	05-08-2003
		MX PA02008240 A	29-11-2002
		NO 20024006 A	22-08-2002
		NZ 520241 A	28-05-2004
		US 2001027196 A1	04-10-2001
		ZA 200206077 A	30-10-2003
WO 2004016605 A	26-02-2004	WO 2004016605 A1	26-02-2004
US 4072746 A	07-02-1978	US 4004012 A	18-01-1977
		AR 220512 A1	14-11-1980
		AR 223137 A1	31-07-1981
		AR 231541 A1	28-12-1984
		AT 362375 B	11-05-1981
		AT 4380 A	15-10-1980
		AT 357534 B	10-07-1980
		AT 48979 A	15-12-1979
		AT 359494 B	10-11-1980
		AT 767476 A	15-04-1980
		AU 1857376 A	20-04-1978
		BE 847196 A1	13-04-1977
		CA 1089860 A1	18-11-1980
		CA 1103253 A2	16-06-1981
		CA 1103254 A2	16-06-1981
		CH 620908 A5	31-12-1980
		CH 619936 A5	31-10-1980
		CH 618969 A5	29-08-1980
		DE 2646469 A1	28-04-1977
		DK 203583 A ,B,	06-05-1983
		DK 455876 A ,B,	15-04-1977
		ES 452405 A1	01-11-1977
		FI 762919 A ,B,	15-04-1977
		FI 65061 B	30-11-1983
		FR 2327779 A1	13-05-1977
		GB 1512129 A	24-05-1978
		GR 64513 A1	09-04-1980
		IE 43956 B1	15-07-1981
		IL 50632 A	30-11-1979
		LU 76011 A1	25-05-1977
		MX 6821 E	06-08-1986
		MX 7114 E	29-06-1987
		NL 7611394 A ,B,	18-04-1977
		NO 763480 A ,B,	15-04-1977
		NO 771952 A ,B,	15-04-1977
		NO 813710 A ,B,	15-04-1977
		NZ 182270 A	28-07-1978
		PH 12507 A	18-04-1979
		PH 20254 A	10-11-1986
		PT 65708 A ,B	01-11-1976

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/JP2004/016193

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4072746 A		SE 430335 B	07-11-1983
		SE 7611376 A	22-06-1977
		SE 441744 B	04-11-1985
		SE 8102022 A	30-03-1981
		US 4225715 A	30-09-1980
		US 4107315 A	15-08-1978
		US 4137233 A	30-01-1979
		US 4199586 A	22-04-1980
		ZA 7606042 A	28-09-1977
US 4313951 A	02-02-1982	AT 379387 B	27-12-1985
		AT 578080 A	15-05-1985
		CA 1143736 A1	29-03-1983
		CA 1155852 A2	25-10-1983
		CH 649535 A5	31-05-1985
		DE 3044568 A1	27-08-1981
		DK 501180 A ,B,	27-05-1981
		EG 14983 A	31-12-1985
		ES 8302661 A1	16-04-1983
		ES 8301920 A3	01-04-1983
		FI 803652 A ,B,	27-05-1981
		FI 854740 A ,B,	29-11-1985
		FR 2470124 A1	29-05-1981
		FR 2553767 A1	26-04-1985
		GB 2065642 A ,B	01-07-1981
		GB 2131421 A ,B	20-06-1984
		GR 71608 A1	17-06-1983
		HK 31189 A	21-04-1989
		HK 83090 A	19-10-1990
		IE 50632 B1	28-05-1986
		IL 61501 A	29-06-1984
		IL 69847 A	29-06-1984
		IT 1148740 B	03-12-1986
		KR 8500025 B1	11-02-1985
		KR 8500317 B2	20-03-1985
		KR 8500632 B2	06-05-1985
		LU 82957 A1	04-06-1981
		MX 158257 A	18-01-1989
		NL 970028 I1	01-10-1997
		NL 8006399 A ,B,	16-06-1981
		NO 803550 A ,B,	27-05-1981
		NO 854001 A	27-05-1981
		NO 156127 B	21-04-1987
		NZ 195564 A	30-09-1983
		PH 22629 A	28-10-1988
		PT 72106 A ,B	01-12-1980
		SE 442398 B	23-12-1985
		SE 8008252 A	27-05-1981
		US 4365065 A	21-12-1982
		AT 379386 B	27-12-1985
		AT 95983 A	15-05-1985
		AU 551627 B2	08-05-1986
		AU 2475384 A	05-07-1984
		AU 536354 B2	03-05-1984
		AU 6455780 A	04-06-1981
		BE 886336 A1	25-05-1981
		JP 1639011 C	31-01-1992
		JP 2050903 B	05-11-1990

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/JP2004/016193

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4313951 A		JP 60214776 A	28-10-1985
		JP 1391523 C	23-07-1987